<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">RSC Adv</journal-id><journal-id journal-id-type="iso-abbrev">RSC Adv</journal-id><journal-id journal-id-type="publisher-id">RA</journal-id><journal-id journal-id-type="coden">RSCACL</journal-id><journal-title-group><journal-title>RSC Advances</journal-title></journal-title-group><issn pub-type="epub">2046-2069</issn><publisher><publisher-name>The Royal Society of Chemistry</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40013064</article-id><article-id pub-id-type="pmc">PMC11862990</article-id><article-id pub-id-type="publisher-id">d4ra08958h</article-id><article-id pub-id-type="doi">10.1039/d4ra08958h</article-id><article-categories><subj-group subj-group-type="heading"><subject>Chemistry</subject></subj-group></article-categories><title-group><article-title>Utility of 6-aza-2-thiothymine in the synthesis of novel [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives: synthesis, structure elucidation, molecular docking and <italic toggle="yes">in vitro</italic> anti-lung cancer activity<xref rid="fn1" ref-type="fn">&#x02020;</xref></article-title><fn-group><fn id="fn1"><label>&#x02020;</label><p>Electronic supplementary information (ESI) available. CCDC <uri>2390251</uri>. For ESI and crystallographic data in CIF or other electronic format see DOI: <uri xlink:href="https://doi.org/10.1039/d4ra08958h">https://doi.org/10.1039/d4ra08958h</uri></p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kamel</surname><given-names>Monica G.</given-names></name><xref rid="affa" ref-type="aff">a</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1283-2157</contrib-id><name><surname>Sroor</surname><given-names>Farid M.</given-names></name><xref rid="affb" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Mahmoud</surname><given-names>Khaled</given-names></name><xref rid="affc" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Shafey</surname><given-names>Heba I.</given-names></name><xref rid="affd" ref-type="aff">d</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hassaneen</surname><given-names>Hamdi M.</given-names></name><xref rid="affa" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Vendier</surname><given-names>Laure</given-names></name><xref rid="affe" ref-type="aff">e</xref></contrib><aff id="affa">
<label>a</label>
<institution>Department of Chemistry, Faculty of Science, Cairo University</institution>
<city>Giza</city>
<country>Egypt</country>
<email>hamdi_251@yahoo.com</email>
<email>hhassaneen@sci.cu.edu.eg</email>
</aff><aff id="affb">
<label>b</label>
<institution>Organometallic and Organometalloid Chemistry Department, National Research Centre</institution>
<city>12622 Cairo</city>
<country>Egypt</country>
<email>faridsroor@gmx.de</email>
<email>fm.sroor@nrc.sci.eg</email>
</aff><aff id="affc">
<label>c</label>
<institution>Pharmacognosy Department, Pharmaceutical and Drug Industry Institute, National Research Centre</institution>
<city>12622-Dokki</city>
<country>Egypt</country>
</aff><aff id="affd">
<label>d</label>
<institution>Cell Biology Department, National Research Centre</institution>
<city>12622-Dokki</city>
<country>Egypt</country>
</aff><aff id="affe">
<label>e</label>
<institution>LCC-CNRS, Universit&#x000e9; de Toulouse, CNRS, UPS</institution>
<city>Toulouse</city>
<country>France</country>
</aff></contrib-group><pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-02-26"><day>26</day><month>2</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2025-02-19"><day>19</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>15</volume><issue>8</issue><fpage>6015</fpage><lpage>6031</lpage><history><date date-type="received" iso-8601-date="2024-12-22"><day>22</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-02-08"><day>8</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>This journal is &#x000a9; The Royal Society of Chemistry</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Royal Society of Chemistry</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense" start_date="2025-02-26">https://creativecommons.org/licenses/by/3.0/</ali:license_ref><license-p>This article is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/3.0/">Creative Commons Attribution 3.0 Unported Licence</ext-link>. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.</license-p></license></permissions><abstract><p>Using 6-aza-2-thiothymine (ATT) as a suitable precursor, a novel series of [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j) was prepared by refluxing 6-methyl-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2<italic toggle="yes">H</italic>)-one (3) with hydrazonoyl halides (1a&#x02013;j) in chloroform in the presence of triethylamine. The structures of the newly synthesized compounds 7a&#x02013;j were confirmed using spectral data, elemental analyses, and single-crystal X-ray diffraction results. All the synthesized triazolotriazin-7-one derivatives (7a&#x02013;j) were evaluated as <italic toggle="yes">in vitro</italic> anti-cancer agents against PC3 (prostate cell line), A549 (lung carcinoma), PACA2 (pancreatic cancer cell line) and BJ1 (normal skin fibroblast) cell lines using MTT assay. Compounds 7a and 7g showed greater efficacy and low IC<sub>50</sub> values (36.6 and 40.1 &#x003bc;M, respectively) compared to the reference drug, which exhibited an IC<sub>50</sub> value of 43.8 &#x003bc;M on the lung cell line, and demonstrated safe mortality effect on the normal cell line (BJ1) with cytotoxicity percentages of 3.5% and 2.8%, respectively. These compounds (7a and 7g) were the most active compounds of the synthesized triazolotriazin-7-one derivatives (7a&#x02013;j). They were further investigated to ascertain their mechanism of action using DNA fragmentation, DNA damage and gene expression (BCL-2, BAX, and p53 genes). Results indicated a significant increase in the expression levels of BCL-2 and a reduction in the expression of p53 and BAX genes in negative lung cancer cell lines. However, the treatment of negative cell lines with 7g improved the expression of the tested genes to a greater extent than that with 7a. Additionally, the DNA damage and DNA fragmentation levels were significantly elevated in the lung cancer cell line samples treated with 7a much more than 7g. Molecular docking was employed to explore the potential interactions between the most active compounds (7a and 7g) and two key enzymes, human 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1), which play vital roles in the progression of lung cancer.</p></abstract><abstract abstract-type="toc"><p>Novel triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j) were synthesized and tested against PC3, A549, PACA2 and BJ1 cell lines. 7a and 7g were investigated using DNA fragmentation, DNA damage and gene expression and molecular docking studies.<graphic xlink:href="d4ra08958h-ga.jpg" id="ga" position="float"/></p></abstract><counts><page-count count="17"/></counts><custom-meta-group><custom-meta><meta-name>pubstatus</meta-name><meta-value>Paginated Article</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><title>Introduction</title><p>Triazolotriazine moiety has attracted significant interest in medicinal chemistry owing to its unusual structural and electrical characteristics, which improve the efficacy of therapeutic candidates.<sup><xref rid="cit1" ref-type="bibr">1&#x02013;4</xref></sup> Its core is useful in the development of nucleoside analogs and other therapeutic medicines because it shows enhanced lipophilicity and improved binding interactions with biological targets.<sup><xref rid="cit1" ref-type="bibr">1,5</xref></sup> Its incorporation in potential drug candidates has been demonstrated to improve antiviral and anti-cancer properties, mainly by increasing the drug's potency and selectivity against particular enzymes and receptors.<sup><xref rid="cit6" ref-type="bibr">6,7</xref></sup> Furthermore, triazolotriazine moiety can improve the pharmacokinetic profiles of drugs and stabilize nucleic acid structures, enhancing bioavailability and lowering toxicity, respectively.<sup><xref rid="cit7" ref-type="bibr">7,8</xref></sup> The significance of triazolotriazine derivatives in the synthesis of novel therapeutic agents highlights their potential for treating a range of diseases, such as cancer and viral infections.</p><p>Lung cancer continues to be one of the most widespread and lethal types of cancer worldwide, causing serious problems to public health.<sup><xref rid="cit9" ref-type="bibr">9,10</xref></sup> Often discovered at an advanced stage, this disease is characterized by the uncontrolled proliferation of aberrant cells in the lungs, which results in poor prognosis and limited therapeutic options.<sup><xref rid="cit11" ref-type="bibr">11</xref></sup> The majority of lung cancer cases are caused by smoking, which is one of the main causes of the disease; however, risk factors for non-smokers include genetic predisposition, radon exposure, and environmental pollution.<sup><xref rid="cit12" ref-type="bibr">12</xref></sup> Moreover, the heterogeneity of lung cancer, which results in different subtypes displaying unique molecular profiles, makes treatment plans more challenging to implement and calls for personalized approaches.<sup><xref rid="cit13" ref-type="bibr">13</xref></sup> Targeted therapy and immunotherapy have made significant advances in lung cancer. However, issues including drug resistance, treatment expenses, and the necessity for early diagnostic technologies make it difficult to manage patients effectively and increase survival rates.<sup><xref rid="cit14" ref-type="bibr">14,15</xref></sup> Addressing these challenges requires an integrated strategy that includes prevention, early diagnosis, and the development of innovative therapeutic strategies, including discovering new drugs to improve the outcomes for patients with lung cancer.</p><p>Given the above information, the purpose of this study was to design and synthesize novel triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j) as the triazolotriazine family using 6-aza-2-thiothymine (ATT) as a suitable precursor and evaluate their anti-cancer activity against various cancer cell lines, including the PC3 (Prostate cell line), A549 (Lung carcinoma), PACA2 (Pancreatic cancer cell line) and BJ1 (normal skin fibroblast). The synthesis of the triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives was of special interest since these compounds were not investigated in previous studies. The most promising compounds (7a and 7g) were examined in further studies to determine their mechanism of action using DNA fragmentation, DNA damage and gene expression (BCL-2, BAX, and p53 genes) as well as molecular docking.</p></sec><sec><title>Results and discussion</title><sec><title>Chemistry</title><p>The reaction of 6-methyl-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2<italic toggle="yes">H</italic>)-one (3)<sup><xref rid="cit16" ref-type="bibr">16</xref></sup> with hydrazonoyl halides (1a&#x02013;j) in refluxing chloroform in the presence of triethylamine yielded a single product in each case (7a&#x02013;j), as shown in <xref rid="sch1" ref-type="fig">Scheme 1</xref> and <xref rid="fig1" ref-type="fig">Fig. 1</xref>. In order to clarify the preceding results, <xref rid="sch2" ref-type="fig">Scheme 2</xref> proposes two plausible mechanistic sequences. In the first sequence (route A in <xref rid="sch2" ref-type="fig">Scheme 2</xref>), nitrilimines (2), which are generated <italic toggle="yes">in situ</italic> by the base-catalyzed dehydrohalogenation of hydrazonoyl halides (1),<sup><xref rid="cit17" ref-type="bibr">17&#x02013;21</xref></sup> are thought to undergo 1,3-dipolar cycloaddition with the C<private-char name="DOUBLE BOND, LENGTH AS M-DASH" description="double bond, length as m-dash"><!-- PBM data was replaced with SVG by xgml2pxml:
<glyph-data id="z.dbd" format="PBM" resolution="300" x-size="8" y-size="10" xml:space="preserve">
00000000
00000000
00000000
00000000
11111111
00000000
11111111
00000000
00000000
00000000
</glyph-data>
-->
<glyph-data id="z.dbd" format="SVG" resolution="300" x-size="8" y-size="10" xml:space="preserve">
<![CDATA[
<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>
]]>
</glyph-data></private-char>S double bond of triazinethione (3), resulting in the spiro intermediate 4, which is then subjected to a base-catalyzed ring cleavage to yield thiohydrazide (5). Subsequent intramolecular cyclization of 5 may result in two distinct heterocyclic intermediates, 6 and 8, which quickly lose hydrogen sulfide to form triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one (7) or triazolo[3,4-<italic toggle="yes">c</italic>][1,2,4]triazin-5-one (9), respectively. In the intermediate 5, the less nucleophilic nitrogen (N-4) could lead to a preferential ring closure to form [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one (7) owing to the electronic effect of the carbonyl group.<sup><xref rid="cit22" ref-type="bibr">22</xref></sup> As an alternative, the reaction could include primary 1,3-addition, which results in amidrazones (10) that cyclize to give intermediate 11 and then compound 7 by the loss of hydrogen sulfide, as shown in route B in <xref rid="sch2" ref-type="fig">Scheme 2</xref>. It is suggested that route A is more likely to occur considering the following factors: (1) a C<private-char name="DOUBLE BOND, LENGTH AS M-DASH" description="double bond, length as m-dash"><glyph-ref glyph-data="z.dbd"/></private-char>S double bond appears to be a more reactive dipolarophile toward different 1,3-dipoles, (2) amidrazones of type 10 are known to be stable, but despite this, every attempt to separate them from the reaction mixtures was unsuccessful; (3) triazine-3-thione derivatives are mainly found in thione structures.<sup><xref rid="cit23" ref-type="bibr">23</xref></sup></p><fig position="float" id="sch1" fig-type="scheme"><label>Scheme 1</label><caption><title>Synthesis of [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives 7a&#x02013;j.</title></caption><graphic xlink:href="d4ra08958h-s1" position="float"/></fig><fig position="float" id="fig1"><label>Fig. 1</label><caption><title>Chemical structures of all the synthesized [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j).</title></caption><graphic xlink:href="d4ra08958h-f1" position="float"/></fig><fig position="float" id="sch2" fig-type="scheme"><label>Scheme 2</label><caption><title>Plausible mechanism of the synthesis of [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j).</title></caption><graphic xlink:href="d4ra08958h-s2" position="float"/></fig><p>The structures of the isolated products were identified by their elemental analyses and spectroscopic data (<sup>1</sup>H NMR and <sup>13</sup>C NMR). Their structures were assigned to be 7 rather than the isomeric structure 9 (<xref rid="sch1" ref-type="fig">Scheme 1</xref> and <xref rid="fig1" ref-type="fig">Fig. 1</xref>). For example, the <sup>1</sup>H NMR spectrum of compound 7b showed the following signals: triplet at <italic toggle="yes">&#x003b4;</italic> 1.48 corresponding to the methyl protons in CH<sub>2</sub>C&#x00048;&#x00332;<sub>3</sub>, singlet at <italic toggle="yes">&#x003b4;</italic> 2.45 corresponding to CH<sub>3</sub> group protons, quartet at <italic toggle="yes">&#x003b4;</italic> 3.03 corresponding to the methylene protons in C&#x00048;&#x00332;<sub>2</sub>CH<sub>3</sub> and pair of doublets at <italic toggle="yes">&#x003b4;</italic> 8.30 and 8.45 corresponding to the protons of 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>. Also, its <sup>13</sup>C NMR spectrum showed 11 signals for asymmetric carbon atoms. Moreover, the single crystal X-ray structure of 7b confirmed the formation of a [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one scaffold (<xref rid="tab1" ref-type="table">Table 1</xref> and <xref rid="fig2" ref-type="fig">Fig. 2</xref>).</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><title>Crystal structure data and details of the structure refinement for compound 7b</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><tbody><tr><td rowspan="1" colspan="1">CCDC deposition number</td><td rowspan="1" colspan="1">
<uri>2390251</uri>
</td><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003bc;</italic> (Cu K<sub>&#x003b1;</sub>)/mm<sup>&#x02212;1</sup></td><td rowspan="1" colspan="1">0.95</td></tr><tr><td rowspan="1" colspan="1">Chemical formula sum</td><td rowspan="1" colspan="1">C<sub>13</sub>H<sub>13</sub>N<sub>6</sub>O<sub>3</sub></td><td rowspan="1" colspan="1">Crystal size/mm</td><td rowspan="1" colspan="1">0.19 &#x000d7; 0.18 &#x000d7; 0.14</td></tr><tr><td rowspan="1" colspan="1">Formula weight/g mol<sup>&#x02212;1</sup></td><td rowspan="1" colspan="1">301.28</td><td rowspan="1" colspan="1">
<italic toggle="yes">T</italic>/K</td><td rowspan="1" colspan="1">100</td></tr><tr><td rowspan="1" colspan="1">Crystal color and shape</td><td rowspan="1" colspan="1">Orange, Bloc</td><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003b8;</italic> rang/&#x000b0;</td><td rowspan="1" colspan="1">4.2&#x02013;79.4</td></tr><tr><td rowspan="1" colspan="1">Crystal system</td><td rowspan="1" colspan="1">Monoclinic</td><td rowspan="1" colspan="1">Reflections collected</td><td rowspan="1" colspan="1">2840</td></tr><tr><td rowspan="1" colspan="1">Space group</td><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic>2<sub>1</sub>/<italic toggle="yes">n</italic></td><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003bb;</italic> (&#x000c5;)</td><td rowspan="1" colspan="1">1.54184</td></tr><tr><td colspan="4" rowspan="1">Unit cell parameters</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">a</italic> (&#x000c5;)</td><td rowspan="1" colspan="1">8.0047 (3)</td><td rowspan="1" colspan="1">
<italic toggle="yes">F</italic>000</td><td rowspan="1" colspan="1">628</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">b</italic> (&#x000c5;)</td><td rowspan="1" colspan="1">21.1874 (6)</td><td rowspan="1" colspan="1">Extinction correction</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">c</italic> (&#x000c5;)</td><td rowspan="1" colspan="1">8.0296 (3)</td><td rowspan="1" colspan="1">
<italic toggle="yes">R</italic>
<sub>Int</sub>
</td><td rowspan="1" colspan="1">0.042</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003b1;</italic> (&#x000b0;)</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">Parameters/restraints</td><td rowspan="1" colspan="1">203/4</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003b2;</italic> (&#x000b0;)</td><td rowspan="1" colspan="1">104.314 (4)</td><td rowspan="1" colspan="1">
<italic toggle="yes">R</italic>[<italic toggle="yes">F</italic><sup>2</sup> &#x0003e; 2<italic toggle="yes">&#x003c3;</italic>(<italic toggle="yes">F</italic><sup>2</sup>)]</td><td rowspan="1" colspan="1">0.043</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">&#x003b3;</italic> (&#x000b0;)</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">
<italic toggle="yes">wR</italic>(<italic toggle="yes">F</italic><sup>2</sup>)</td><td rowspan="1" colspan="1">0.1294</td></tr><tr><td rowspan="1" colspan="1">Unit cell volume/&#x000c5;<sup>3</sup></td><td rowspan="1" colspan="1">1319.53 (9)</td><td rowspan="1" colspan="1">Goodness-of-fit on <italic toggle="yes">F</italic><sup>2</sup></td><td rowspan="1" colspan="1">0.9825</td></tr><tr><td rowspan="1" colspan="1">Molecules per cell <italic toggle="yes">Z</italic></td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">1-Sigma level</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Calcd density <italic toggle="yes">&#x003c1;</italic>/g cm<sup>&#x02212;3</sup></td><td rowspan="1" colspan="1">1.516</td><td rowspan="1" colspan="1">Highest difference peak and hole/e &#x000c5;<sup>&#x02212;3</sup></td><td rowspan="1" colspan="1">0.29/&#x02212;0.64</td></tr></tbody></table></table-wrap><fig position="float" id="fig2"><label>Fig. 2</label><caption><title>Single-crystal structure of 3-ethyl-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7b). H atoms are omitted for clarity. Selected bond lengths [&#x000c5;]: N7&#x02013;N6 1.3721(14), N9&#x02013;N1 1.3969(14), N7&#x02013;C2 1.3648(16), C2&#x02013;N1 1.3634 (15), N3&#x02013;C2 1.3119(16), C10&#x02013;N1 1.4156(15), O19&#x02013;C4 1.2236(16), C22&#x02013;C5 1.4916(17), O17&#x02013;N16 1.2289(15), O18&#x02013;N16 1.2285(15). Selected bond angles [&#x000b0;]: C8&#x02013;N9&#x02013;N1 106.15(10), O17&#x02013;N16&#x02013;O18 123.50(11), N6&#x02013;N7&#x02013;C8 126.81(11), N6&#x02013;N7&#x02013;C2 123.68(11), C8&#x02013;N7&#x02013;C2 109.18(10), N9&#x02013;N1&#x02013;C2 110.77(10), N3&#x02013;C2&#x02013;N1 130.12(11).</title></caption><graphic xlink:href="d4ra08958h-f2" position="float"/></fig><p>As depicted in <xref rid="tab1" ref-type="table">Table 1</xref> and <xref rid="fig2" ref-type="fig">Fig. 2</xref>, single crystals containing 7b were found to be suitable for single-crystal X-ray diffraction. The crystal structure of compound 7b was deposited at Cambridge Crystallographic Data Centre under CCDC number <uri>2390251</uri>. It was produced as orange crystals from a saturated DMF/acetonitrile solution at ambient temperature. Compound 7b forms a single molecule in the unit cell and crystallizes in the monoclinic cell with space group <italic toggle="yes">P</italic>2<sub>1</sub>/<italic toggle="yes">n</italic> (<xref rid="tab1" ref-type="table">Table 1</xref>). The presence of the fused [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one scaffold was clearly elucidated by the crystal structure determination of 3-ethyl-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7b) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). The selected examples of the bond lengths and angles of the [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one moiety, the distances of N7&#x02013;N6 is 1.3721(14), N9&#x02013;N1 is 1.3969(14), N7&#x02013;C2 is 1.3648(16), C2&#x02013;N1 is 1.3634 (15), N3&#x02013;C2 is 1.3119(16), and C10&#x02013;N1 is 1.4156(15), and the angles C8&#x02013;N9&#x02013;N1 is 106.15(10), O17&#x02013;N16&#x02013;O18 is 123.50(11), and N6&#x02013;N7&#x02013;C8 is 126.81(11), are in good agreement with those reported for 5-(4-bromophenyl)-4,6-dichloro-7-(2,4-dichlorophenyl)-7<italic toggle="yes">H</italic>-pyrrolo[2,3-<italic toggle="yes">d</italic>]pyrimidine, 4-amino-7-nitro-[1,2,4]triazolo[5,1-<italic toggle="yes">c</italic>][1,2,4]triazine-3-carbonitrile and 4,6-dichloro-7-(2,4-dichlorophenyl)-5-(3,4-dimethoxyphenyl)-7<italic toggle="yes">H</italic>-pyrrolo[2,3-<italic toggle="yes">d</italic>]pyrimidine.<sup><xref rid="cit3" ref-type="bibr">3,24,25</xref></sup> More selected bond lengths and angles are shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref> (see ESI<xref rid="fn1" ref-type="fn">&#x02020;</xref>).</p></sec><sec><title>Anti-cancer activity</title><sec><title>
<italic toggle="yes">In vitro</italic> cytotoxicity using MTT assay</title><p>Using specific human cancer cell lines, the anti-proliferative effectiveness of compounds 7a&#x02013;j was evaluated in an <italic toggle="yes">in vitro</italic> assay. The anti-cancer activity of these compounds (7a&#x02013;j) on various cancer cell lines, including PC3 (Prostate cell line), A549 (Lung carcinoma), PACA2 (Pancreatic cancer cell line) and BJ1 (normal skin fibroblast), was investigated in this study using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. Doxorubicin (Dox) was the standard medication used as a positive control.</p><p>In the initial screening trial, a single dosage concentration of 100 &#x003bc;g ml<sup>&#x02212;1</sup> was applied for 48 hours. The cytotoxicity of the treated cells was determined by calculating the cell death percentage (% mortality) as a percentage of untreated cells (<xref rid="tab2" ref-type="table">Table 2</xref>). Against the lung cancer cell lines (A549), the results demonstrated that four compounds, 7a, 7e, 7f and 7g, had considerable cytotoxic activity (80.4, 86.3, 69.1, and 82.3%, respectively), while compounds 7b, 7d and 7j showed limited cytotoxic effects of 35.2, 33.3 and 32.8%, respectively (<xref rid="tab2" ref-type="table">Table 2</xref>). In the case of the prostate cell line (PC3), all compounds showed limited anti-cancer activity with mortality in the range of 15.9&#x02013;35.1%, as depicted in <xref rid="tab2" ref-type="table">Table 2</xref>. All the synthesized triazolotriazin-7-one derivatives (7a&#x02013;j) demonstrated a low cytotoxic effect on the pancreatic cancer cell line (PACA2), as shown in <xref rid="tab2" ref-type="table">Table 2</xref>. Additionally, to confirm the safety of the most effective compounds against cancer cells, their cytotoxicity was assessed against normal cells (BJ1). As visualized in <xref rid="tab1" ref-type="table">Table 1</xref>, the most promising compounds, 7a, 7e, 7f and 7g, were found to be safe on the normal cells (BJ1) up to a concentration of 100 &#x003bc;g ml<sup>&#x02212;1</sup> with cytotoxicity percentages 3.5%, 6.4%, 3.2%, and 2.8%, respectively.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><title>(%) Mortality of cancer and normal cell lines at 100 &#x003bc;g ml<sup>&#x02212;1</sup> of compounds 7a&#x02013;j and IC<sub>50</sub> (&#x003bc;M) values of the most active compounds</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Compound</th><th rowspan="1" colspan="1">PC3 (IC<sub>50</sub>, &#x003bc;M)</th><th rowspan="1" colspan="1">A549 (IC<sub>50</sub>, &#x003bc;M)</th><th rowspan="1" colspan="1">PACA2 (IC<sub>50</sub>, &#x003bc;M)</th><th rowspan="1" colspan="1">BJ1</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">7a</td><td rowspan="1" colspan="1">28.2 &#x000b1; 0.25</td><td rowspan="1" colspan="1">80.4 &#x000b1; 0.66 (36.6 &#x000b1; 0.33)</td><td rowspan="1" colspan="1">20.4 &#x000b1; 0.11</td><td rowspan="1" colspan="1">3.5 &#x000b1; 1.16</td></tr><tr><td rowspan="1" colspan="1">7b</td><td rowspan="1" colspan="1">24.5 &#x000b1; 0.57</td><td rowspan="1" colspan="1">35.2 &#x000b1; 1.22</td><td rowspan="1" colspan="1">3.6 &#x000b1; 0.21</td><td rowspan="1" colspan="1">4.2 &#x000b1; 0.98</td></tr><tr><td rowspan="1" colspan="1">7c</td><td rowspan="1" colspan="1">27.3 &#x000b1; 1.20</td><td rowspan="1" colspan="1">22.9 &#x000b1; 0.81</td><td rowspan="1" colspan="1">10.5 &#x000b1; 0.61</td><td rowspan="1" colspan="1">1.6 &#x000b1; 0.38</td></tr><tr><td rowspan="1" colspan="1">7d</td><td rowspan="1" colspan="1">17.9 &#x000b1; 0.38</td><td rowspan="1" colspan="1">33.3 &#x000b1; 0.22</td><td rowspan="1" colspan="1">11.5 &#x000b1; 0.25</td><td rowspan="1" colspan="1">36.2 &#x000b1; 1.11</td></tr><tr><td rowspan="1" colspan="1">7e</td><td rowspan="1" colspan="1">35.1 &#x000b1; 1.11</td><td rowspan="1" colspan="1">86.3 &#x000b1; 0.74 (<bold>42.5</bold> &#x000b1; <bold>0.27</bold>)</td><td rowspan="1" colspan="1">8.6 &#x000b1; 0.33</td><td rowspan="1" colspan="1">6.4 &#x000b1; 0.85</td></tr><tr><td rowspan="1" colspan="1">7f</td><td rowspan="1" colspan="1">33.4 &#x000b1; 1.18</td><td rowspan="1" colspan="1">69.1 &#x000b1; 0.77</td><td rowspan="1" colspan="1">5.6 &#x000b1; 0.11</td><td rowspan="1" colspan="1">3.2 &#x000b1; 0.63</td></tr><tr><td rowspan="1" colspan="1">7g</td><td rowspan="1" colspan="1">14.6 &#x000b1; 0.92</td><td rowspan="1" colspan="1">82.3 &#x000b1; 0.82 (<bold>40.1</bold> &#x000b1; <bold>0.84</bold>)</td><td rowspan="1" colspan="1">13.4 &#x000b1; 1.15</td><td rowspan="1" colspan="1">2.8 &#x000b1; 0.71</td></tr><tr><td rowspan="1" colspan="1">7h</td><td rowspan="1" colspan="1">24.2 &#x000b1; 0.21</td><td rowspan="1" colspan="1">13.5 &#x000b1; 0.33</td><td rowspan="1" colspan="1">21.3 &#x000b1; 0.98</td><td rowspan="1" colspan="1">9.6 &#x000b1; 0.93</td></tr><tr><td rowspan="1" colspan="1">7i</td><td rowspan="1" colspan="1">18.4 &#x000b1; 1.14</td><td rowspan="1" colspan="1">14.2 &#x000b1; 0.24</td><td rowspan="1" colspan="1">9.6 &#x000b1; 1.33</td><td rowspan="1" colspan="1">2.9 &#x000b1; 1.22</td></tr><tr><td rowspan="1" colspan="1">7j</td><td rowspan="1" colspan="1">15.9 &#x000b1; 0.51</td><td rowspan="1" colspan="1">32.8 &#x000b1; 0.54</td><td rowspan="1" colspan="1">7.2 &#x000b1; 0.88</td><td rowspan="1" colspan="1">3.8 &#x000b1; 0.77</td></tr><tr><td rowspan="1" colspan="1">Dox</td><td rowspan="1" colspan="1">100 (<bold>43.78</bold> &#x000b1; <bold>0.54</bold>)</td><td rowspan="1" colspan="1">100 (<bold>43.80</bold> &#x000b1; <bold>0.17</bold>)</td><td rowspan="1" colspan="1">100 (<bold>52.06</bold> &#x000b1; <bold>0.42</bold>)</td><td rowspan="1" colspan="1">1.10 &#x000b1; 0.52</td></tr><tr><td rowspan="1" colspan="1">Negative control</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>Based on the results of <xref rid="tab2" ref-type="table">Table 2</xref>, we continued our investigation into the molecular mechanisms underlying the potent lethal impact of the most active compounds on lung cancer cells (A549). Compounds 7a, 7e, 7f, and 7g showed limited mortality and high safety on the normal cells. Hence, secondary screening was performed on these compounds to ascertain their IC<sub>50</sub> values and selectivity index. <xref rid="tab2" ref-type="table">Table 2</xref> illustrates that compounds 7a, 7e, and 7g had greater efficacy (IC<sub>50</sub> values of 36.6, 42.5, and 40.1 &#x003bc;M, respectively) in comparison to the reference drug with an IC<sub>50</sub> of 43.8 &#x003bc;M. Accordingly, compounds 7a and 7g with low IC<sub>50</sub> values (36.6 and 40.1 &#x003bc;M, respectively) and safe mortality effect on the normal cell line (BJ1) with cytotoxicity percentages of 3.5, and 2.8%, respectively, are the most active compounds of the synthesized triazolotriazin-7-one derivatives (7a&#x02013;j). Thus, in order to explore the potential mode of action of compounds 7a and 7g as powerful anti-lung cancer agents, we selected them for further studies. We used comet, RT-PCR, and DNA fragmentation tests to examine the effects of these compounds at the gene, protein, and DNA levels.</p></sec><sec><title>Gene expression in lung cancer cell lines</title><p>The study of the expression of BCL-2, p53, and BAX in lung cancer cell lines treated with compounds 7a, 7g, and Dox is presented in <xref rid="fig3 fig4 fig5" ref-type="fig">Fig. 3&#x02013;5</xref>. The results indicated a significant increase (<italic toggle="yes">P</italic> &#x0003c; 0.01) in the expression levels of the anti-apoptotic gene BCL-2 in negative samples of the lung cancer cell lines compared to the treated cell lines (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).</p><fig position="float" id="fig3"><label>Fig. 3</label><caption><title>Alterations in the BCL-2 gene expression in lung cancer cell lines treated with 7a and 7g as well as Dox (as positive control). Data are presented as mean &#x000b1; SEM. <sup>a, b, c</sup>: Mean values within the tissue with unlike superscript letters were significantly different (<italic toggle="yes">P</italic> &#x0003c; 0.05).</title></caption><graphic xlink:href="d4ra08958h-f3" position="float"/></fig><p>Nonetheless, the expression levels of the pro-apoptotic genes (p53 and BAX) were dramatically diminished in the negative samples of lung cancer cell lines compared to the treated lung cancer cell lines (<xref rid="fig4" ref-type="fig">Fig. 4</xref> and <xref rid="fig5" ref-type="fig">5</xref>). The expression levels of the anti-apoptotic gene BCL-2 were diminished in descending order in the cancer cell lines treated with 7g, Dox, and subsequently 7a in comparison to the negative control cancer cell lines. The expression levels of the pro-apoptotic genes (p53 and BAX) were elevated in a sequential manner in the cancer cell line treated with 7g, followed by Dox, and subsequently 7a, in comparison to the negative control cancer cell lines.</p><fig position="float" id="fig4"><label>Fig. 4</label><caption><title>Alterations in the p53 gene expression in lung cancer cell lines treated with 7a and 7g as well as Dox. Data are presented as mean &#x000b1; SEM. <sup>a, b, c</sup>: Mean values within the tissue with unlike superscript letters were significantly different (<italic toggle="yes">P</italic> &#x0003c; 0.05).</title></caption><graphic xlink:href="d4ra08958h-f4" position="float"/></fig><fig position="float" id="fig5"><label>Fig. 5</label><caption><title>Alterations in the BAX gene expression in lung cancer cell lines treated with 7a and 7g as well as Dox. Data are presented as mean &#x000b1; SEM. <sup>a, b, c</sup>: Mean values within the tissue with unlike superscript letters were significantly different (<italic toggle="yes">P</italic> &#x0003c; 0.05).</title></caption><graphic xlink:href="d4ra08958h-f5" position="float"/></fig><p>The results indicated that the anti-cancer action of the examined drugs was most prominently detected in 7g, followed by Dox, and subsequently 7a. Compound 7a showed much greater efficacy against the tumor cell line compared to 7g.</p></sec><sec><title>DNA damage evaluation using the comet assay</title><p>The DNA damage in lung cancer cell lines was assessed using the comet test, as illustrated in <xref rid="tab3" ref-type="table">Table 3</xref> and <xref rid="fig6" ref-type="fig">Fig. 6</xref>. The findings indicated that the negative lung cancer cell lines demonstrated a notable reduction (<italic toggle="yes">P</italic> &#x0003c; 0.05) in DNA damage values (11.59 &#x000b1; 0.65). However, the DNA damage levels were significantly elevated (<italic toggle="yes">P</italic> &#x0003c; 0.01) in the lung cancer cell line samples treated with 7a (28.181.25), Dox medication (23.861.11), and 7g (21.140.85) in comparison to the negative control.</p><table-wrap position="float" id="tab3"><label>Table 3</label><caption><title>Visual score of the DNA damage in lung cancer cell lines treated with 7a and 7g</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="2" colspan="1">Treatment</th><th rowspan="2" colspan="1">No. of samples</th><th colspan="2" rowspan="1">No. of cells</th><th colspan="4" rowspan="1">Class<xref rid="tab3fnb" ref-type="table-fn">b</xref></th><th rowspan="2" colspan="1">DNA damaged cells% (mean &#x000b1; SEM)</th></tr><tr><th rowspan="1" colspan="1">Analyzed<xref rid="tab3fna" ref-type="table-fn">a</xref></th><th rowspan="1" colspan="1">Comets</th><th rowspan="1" colspan="1">0</th><th rowspan="1" colspan="1">1</th><th rowspan="1" colspan="1">2</th><th rowspan="1" colspan="1">3</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">A549 (&#x02212;ve)</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">440</td><td align="char" char="." rowspan="1" colspan="1">51</td><td align="char" char="." rowspan="1" colspan="1">389</td><td align="char" char="." rowspan="1" colspan="1">35</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="xb1" rowspan="1" colspan="1">11.59 &#x000b1; 0.65<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">A549 + 7a</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">440</td><td align="char" char="." rowspan="1" colspan="1">124</td><td align="char" char="." rowspan="1" colspan="1">316</td><td align="char" char="." rowspan="1" colspan="1">37</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="char" char="xb1" rowspan="1" colspan="1">28.18 &#x000b1; 1.25<sup>a</sup></td></tr><tr><td rowspan="1" colspan="1">A549 + 7g</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">440</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">347</td><td align="char" char="." rowspan="1" colspan="1">32</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="xb1" rowspan="1" colspan="1">21.14 &#x000b1; 0.85<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">A549 + Dox</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">440</td><td align="char" char="." rowspan="1" colspan="1">105</td><td align="char" char="." rowspan="1" colspan="1">335</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">41</td><td align="char" char="." rowspan="1" colspan="1">30</td><td align="char" char="xb1" rowspan="1" colspan="1">23.86 &#x000b1; 1.11<sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn id="tab3fna"><label>a</label><p>Number of cells examined per group.</p></fn><fn id="tab3fnb"><label>b</label><p>Class 0 = no tail; 1 = tail length &#x0003c; diameter of the nucleus; 2 = tail length between 1&#x000d7; and 2&#x000d7; the diameter of the nucleus; and 3 = tail length &#x0003e; 2&#x000d7; the diameter of the nucleus.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="fig6"><label>Fig. 6</label><caption><title>Visual score of normal DNAs (class 0) and damaged DNAs (class 1, class 2 and class 3) using comet assay in lung cancer cell lines.</title></caption><graphic xlink:href="d4ra08958h-f6" position="float"/></fig></sec><sec><title>Measurement of DNA fragmentation in lung cancer cell lines</title><p>The DNA fragmentation evaluation of compounds 7a and 7g against the lung cancer cell is depicted in <xref rid="fig7" ref-type="fig">Fig. 7</xref> and <xref rid="fig8" ref-type="fig">8</xref> as well as <xref rid="tab4" ref-type="table">Table 4</xref>. However, the DNA fragmentation values increased significantly (<italic toggle="yes">P</italic> &#x0003c; 0.01) in the lung cancer cell line samples treated with 7a (32.78 &#x000b1; 1.35), doxorubicin (28.38 &#x000b1; 1.06) and 7g (25.57 &#x000b1; 0.94) compared with the negative control cancer cell lines (12.54 &#x000b1; 0.45) (<xref rid="tab5" ref-type="table">Table 5</xref>).</p><fig position="float" id="fig7"><label>Fig. 7</label><caption><title>DNA fragmentation detected with agarose gel in A549 cancer cell lines exposed to different compounds. M represents the DNA marker, Lane 1 represents the negative control of A549, Lane 2 represents A549 treated with 7a, Lane 3 represents A549 treated with 7g, and Lane 4 represents A549 treated with Dox.</title></caption><graphic xlink:href="d4ra08958h-f7" position="float"/></fig><fig position="float" id="fig8"><label>Fig. 8</label><caption><title>DNA fragmentation detected in the lung cancer cell lines (A549) treated with different compounds 7a, 7g and Dox. Mean values with different superscripts (<sup>a, b, c</sup>) between treatments in the same column are significantly different at <italic toggle="yes">P</italic> &#x0003c; 0.05.</title></caption><graphic xlink:href="d4ra08958h-f8" position="float"/></fig><table-wrap position="float" id="tab4"><label>Table 4</label><caption><title>DNA fragmentation detected in the lung cancer cell lines in different treatment groups<xref rid="tab4fna" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">DNA fragmentation% (<italic toggle="yes">M</italic> &#x000b1; SEM)</th><th rowspan="1" colspan="1">Change</th><th rowspan="1" colspan="1">Inhibition%</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">A549 (&#x02212;ve)</td><td align="char" char="xb1" rowspan="1" colspan="1">12.54 &#x000b1; 0.45<sup>c</sup></td><td align="char" char="." rowspan="1" colspan="1">0.00</td><td align="char" char="." rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="1" colspan="1">A549 + 7a</td><td align="char" char="xb1" rowspan="1" colspan="1">32.78 &#x000b1; 1.35<sup>a</sup></td><td align="char" char="." rowspan="1" colspan="1">20.24</td><td align="char" char="." rowspan="1" colspan="1">27.78</td></tr><tr><td rowspan="1" colspan="1">A549 + 7g</td><td align="char" char="xb1" rowspan="1" colspan="1">25.57 &#x000b1; 0.94<sup>b</sup></td><td align="char" char="." rowspan="1" colspan="1">13.03</td><td align="char" char="." rowspan="1" colspan="1">17.74</td></tr><tr><td rowspan="1" colspan="1">A549 + Dox</td><td align="char" char="xb1" rowspan="1" colspan="1">28.38 &#x000b1; 1.06<sup>b</sup></td><td align="char" char="." rowspan="1" colspan="1">15.84</td><td align="char" char="." rowspan="1" colspan="1">19.69</td></tr></tbody></table><table-wrap-foot><fn id="tab4fna"><label>a</label><p>Means with different superscripts (<sup>a, b, c</sup>) between groups in the same column are significantly different at <italic toggle="yes">P</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tab5"><label>Table 5</label><caption><title>Molecular docking results of the most active compounds 7a, 7g, and the co-crystalline ligand within the active pocket of 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1)</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Comp. no.</th><th rowspan="1" colspan="1">Score kcal mol<sup>&#x02212;1</sup></th><th rowspan="1" colspan="1">Moieties from compounds</th><th rowspan="1" colspan="1">Amino acid residues</th><th rowspan="1" colspan="1">Type of interaction, distance &#x000c5;</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">
<bold>3-Phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>)</bold>
</td></tr><tr><td rowspan="5" colspan="1">NAD</td><td rowspan="5" align="char" char="." colspan="1">&#x02212;7.7</td><td rowspan="1" colspan="1">CO</td><td rowspan="1" colspan="1">Thr77, Arg235</td><td rowspan="1" colspan="1">H-bonds 3.12, 2.99</td></tr><tr><td rowspan="1" colspan="1">O&#x02013;P<private-char name="DOUBLE BOND, LENGTH AS M-DASH" description="double bond, length as m-dash"><glyph-ref glyph-data="z.dbd"/></private-char>O</td><td rowspan="1" colspan="1">His205, Ser102, Arg154, Ile155, Gly156</td><td rowspan="1" colspan="1">H-bonds 3.12, 3.22, 3.25, 3.20, 2.86, 3.40</td></tr><tr><td rowspan="1" colspan="1">NH<sub>2</sub>, N</td><td rowspan="1" colspan="1">Ser211, Asp174</td><td rowspan="1" colspan="1">H-bonds 3.03, 3.37</td></tr><tr><td rowspan="1" colspan="1">Phenyl ring</td><td rowspan="1" colspan="1">Arg235, Pro207</td><td rowspan="1" colspan="1">Alkyl</td></tr><tr><td rowspan="1" colspan="1">CH<sub>2</sub></td><td rowspan="1" colspan="1">His205</td><td rowspan="1" colspan="1">Carbon&#x02013;H bond</td></tr><tr><td rowspan="4" colspan="1">7a</td><td rowspan="4" align="char" char="." colspan="1">&#x02212;7.8</td><td rowspan="1" colspan="1">NO<sub>2</sub>, N atoms of triazolo-triazine moiety</td><td rowspan="1" colspan="1">Ser211, His205, Asp174</td><td rowspan="1" colspan="1">H-bonds, 3.09, 2.84, 3.13</td></tr><tr><td rowspan="1" colspan="1">Phenyl and triazine rings</td><td rowspan="1" colspan="1">Pro175, Pro207, Thr206</td><td rowspan="1" colspan="1">pi&#x02013;alkyl, pi-sigma</td></tr><tr><td rowspan="2" colspan="1">Triazole ring</td><td rowspan="1" colspan="1">Asp174</td><td rowspan="1" colspan="1">pi&#x02013;anion</td></tr><tr><td rowspan="1" colspan="1">Ile176, Gly153, Arg154</td><td rowspan="1" colspan="1">van der Walls</td></tr><tr><td rowspan="2" colspan="1">7g</td><td rowspan="2" align="char" char="." colspan="1">&#x02212;8.6</td><td rowspan="1" colspan="1">CO</td><td rowspan="1" colspan="1">Gly78</td><td rowspan="1" colspan="1">H-bond 2.33</td></tr><tr><td rowspan="1" colspan="1">Phenyl and triazolo-triazine rings</td><td rowspan="1" colspan="1">Thr77, Ile155, Ala234, Pro207, Arg235</td><td rowspan="1" colspan="1">pi&#x02013;donor H-bond, pi&#x02013;alkyl</td></tr><tr><td colspan="5" rowspan="1">&#x02009;</td></tr><tr><td colspan="5" rowspan="1">
<bold>Phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>)</bold>
</td></tr><tr><td rowspan="3" colspan="1">PLP</td><td rowspan="3" align="char" char="." colspan="1">&#x02212;6.5</td><td rowspan="1" colspan="1">CO, OH, O&#x02013;P<private-char name="DOUBLE BOND, LENGTH AS M-DASH" description="double bond, length as m-dash"><glyph-ref glyph-data="z.dbd"/></private-char>O, N</td><td rowspan="1" colspan="1">Tr153, Lys198, Arg77, Gln197, Gly75, Asp174</td><td rowspan="1" colspan="1">H-bond 3.00, 2.72, 3.01, 2.98, 2.26, 2.85, 3.59</td></tr><tr><td rowspan="2" colspan="1">P<private-char name="DOUBLE BOND, LENGTH AS M-DASH" description="double bond, length as m-dash"><glyph-ref glyph-data="z.dbd"/></private-char>O</td><td rowspan="1" colspan="1">Gly75</td><td rowspan="1" colspan="1">Carbon&#x02013;hydrogen bond</td></tr><tr><td rowspan="1" colspan="1">Trp102</td><td rowspan="1" colspan="1">van der Waals</td></tr><tr><td rowspan="3" colspan="1">7a</td><td rowspan="3" align="char" char="." colspan="1">&#x02212;7.4</td><td rowspan="1" colspan="1">NO<sub>2</sub></td><td rowspan="1" colspan="1">Ser177, Ser176, Thr153</td><td rowspan="1" colspan="1">H-bonds 3.23, 3.18, 2.93, 3.49</td></tr><tr><td rowspan="2" colspan="1">NO, phenyl and triazolo-triazine rings</td><td rowspan="1" colspan="1">Trp102, Gln197, Arg77</td><td rowspan="1" colspan="1">Carbon hydrogen bond, pi&#x02013;donor hydrogen bond, pi&#x02013;pi stacked, pi&#x02013;alkyl interactions</td></tr><tr><td rowspan="1" colspan="1">Cys149</td><td rowspan="1" colspan="1">van der Waals</td></tr><tr><td rowspan="4" colspan="1">7g</td><td rowspan="4" align="char" char="." colspan="1">&#x02212;8.5</td><td rowspan="1" colspan="1">CO, N atom of triazine ring</td><td rowspan="1" colspan="1">Lys198, Trp102, Gly10</td><td rowspan="1" colspan="1">H-bond 3.19, 3.01, 3.09</td></tr><tr><td rowspan="1" colspan="1">Phenyl and 4-chloro phenyl rings</td><td rowspan="1" colspan="1">Pro11, Phe80, Trp102, Arg77</td><td rowspan="1" colspan="1">pi&#x02013;pi stacked, pi&#x02013;alkyl</td></tr><tr><td rowspan="2" colspan="1">Triazole ring</td><td rowspan="1" colspan="1">Lys198</td><td rowspan="1" colspan="1">pi&#x02013;cation</td></tr><tr><td rowspan="1" colspan="1">Gln197</td><td rowspan="1" colspan="1">van der Waals</td></tr></tbody></table></table-wrap></sec><sec><title>Molecular docking</title><p>Molecular docking is a valuable computational technique for assessing the binding interaction between a ligand and the active site of an enzyme or receptor. In this study, molecular docking was employed to explore the potential interactions between the most active compounds (7a and 7g) and two key enzymes, human 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1), which play vital roles in the progression of lung cancer.</p><p>Autodock Vina within PyRx software version 8 was utilized to conduct the docking simulations, and the binding energy was used to report the results for each compound. A lower binding energy value signifies a stronger binding affinity. Hydrogen bonds, the strongest interactions, were examined in conjunction with hydrophobic bonds (carbon&#x02013;hydrogen, van der Waals, Pi&#x02013;anion, Pi&#x02013;cation, Pi&#x02013;sigma, alkyl, Pi&#x02013;alkyl, <italic toggle="yes">etc.</italic>). The binding affinity and interaction characteristics of the selected compounds with the target enzymes are depicted in <xref rid="tab5" ref-type="table">Table 5</xref>. The 2D and 3D docked poses, along with the interactions of the co-crystallized ligand, are illustrated in <xref rid="fig9 fig10 fig11 fig12 fig13 fig14" ref-type="fig">Fig. 9&#x02013;14</xref>. The grid box with the <italic toggle="yes">XYZ</italic> dimensions 10.19 &#x000c5; &#x000d7; 29.38 &#x000c5; &#x000d7; &#x02212;2.48 &#x000c5; and center 25.05, 19.72, 23.93 (<italic toggle="yes">XYZ</italic> coordinates) was defined to cover the 3-phosphoglycerate dehydrogenase binding while for the phosphoserine aminotransferase enzyme (PDB ID: <uri>7T7J</uri>), the grid box was identified to cover pyridoxal-5&#x02032;-phosphate (PLP) with dimensions 16.00 &#x000c5; &#x000d7; 14.48 &#x000c5; &#x000d7; 18.09 &#x000c5; and a center 14.85, 5.89, 11.21 (<italic toggle="yes">X</italic>, <italic toggle="yes">Y</italic>, <italic toggle="yes">Z</italic>).</p><fig position="float" id="fig9"><label>Fig. 9</label><caption><title>(A) 3D conformations of the native (orange), re-docked ligand (yellow), compound 7a (green), and compound 7g (blue) within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>) indicating that they are superimposed in the same position. (B) 2D conformations of the re-docked co-crystalline ligand NAD within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>).</title></caption><graphic xlink:href="d4ra08958h-f9" position="float"/></fig></sec></sec><sec><title>Assessment of the binding affinity of compounds 7a and 7g within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>)</title><p>Firstly, the docking setup was validated by the self-docking of the co-crystallized ligand NAD into the PHGDH active pocket (PDB ID: <uri>2G76</uri>). The docking result indicates that the re-docked NAD was superimposed on the native ligand with a docking score of &#x02212;7.7 kcal mol<sup>&#x02212;1</sup> and formed multiple interactions with the PHGDH active site (<xref rid="fig9" ref-type="fig">Fig. 9A and B</xref>). The NAD revealed intermolecular hydrogen bonds with Thr77, Arg235, His205, Ser102, Arg154, Ile155, Gly156, Ser211, and Asp174 and interacted <italic toggle="yes">via</italic> alkyl and carbon&#x02013;hydrogen hydrophobic interactions with the Arg235, Pro207, and His205 amino acids of the binding site (<xref rid="fig9" ref-type="fig">Fig. 9B</xref>). Furthermore, compounds 7a and 7g were then docked into the PHGDH active site, which demonstrated better docking scores of &#x02212;7.8 and &#x02212;8.6 kcal mol<sup>&#x02212;1</sup> than NAD, respectively, and both of them were superimposed on the same position as the co-crystalline ligand (<xref rid="tab5" ref-type="table">Table 5</xref> and <xref rid="fig9" ref-type="fig">Fig. 9A</xref>). Compound 7a formed a stable complex with the enzyme active pocket by establishing three hydrogen bonds with Ser211, His205, Asp174, Ile176, Gly153, and Arg154 residues, along with various hydrophobic &#x003c0;&#x02013;alkyl, &#x003c0;&#x02013;sigma, &#x003c0;&#x02013;anion, and van der Waals interactions similar to the co-crystalline ligand (<xref rid="fig10" ref-type="fig">Fig. 10</xref>). On the other hand, compound 7g exhibited one hydrogen bond with Gly78, in addition to the &#x003c0;-donor H-bond, &#x003c0;&#x02013;alkyl with Thr77, Ile155, Ala234, Pro207, and Arg235 amino acids (<xref rid="fig11" ref-type="fig">Fig. 11</xref>).</p><fig position="float" id="fig10"><label>Fig. 10</label><caption><title>(A) 3D conformations of compound 7a within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>); (B) 2D conformations of compound 7a within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>).</title></caption><graphic xlink:href="d4ra08958h-f10" position="float"/></fig><fig position="float" id="fig11"><label>Fig. 11</label><caption><title>(A) 3D conformations of compound 7g within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>). (B) 2D conformations of compound 7g within the active site of human 3-phosphoglycerate dehydrogenase (PDB ID: <uri>2G76</uri>).</title></caption><graphic xlink:href="d4ra08958h-f11" position="float"/></fig></sec><sec><title>Assessment of the binding affinity of compounds 7a and 7g within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>)</title><p>The co-crystallized ligand, pyridoxal-5&#x02032;-phosphate (PLP), was re-docked into the active site of PSAT1, and the results showed that the re-docked PLP superimposed on the native ligand, achieving a docking score of &#x02212;6.5 kcal mol<sup>&#x02212;1</sup> (<xref rid="tab5" ref-type="table">Table 5</xref> and <xref rid="fig9" ref-type="fig">Fig. 9A and B</xref>). Analysis of the binding site revealed that PLP formed hydrogen bonds, a carbon H-bond, and van der Waals interactions with the amino acids Thr153, Lys198, Arg77, Gln197, Gly75, Asp174, and Trp102 (<xref rid="tab5" ref-type="table">Table 5</xref> and <xref rid="fig12" ref-type="fig">Fig. 12B</xref>).</p><fig position="float" id="fig12"><label>Fig. 12</label><caption><title>(A) 3D conformations of the native (orange), re-docked ligand (yellow), compound 7a (green), and compound 7g (blue) within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>) indicating that they are superimposed in the same position. (B) 2D conformations of the re-docked co-crystalline ligand PLP within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>).</title></caption><graphic xlink:href="d4ra08958h-f12" position="float"/></fig><p>The docking results for compounds 7a and 7g revealed docking scores of &#x02212;7.4 and &#x02212;8.5, respectively, outperforming the co-crystalline ligand PLP. Both compounds formed stable complexes with the PSAT1 active site and aligned with the same position as PLP (<xref rid="tab5" ref-type="table">Table 5</xref> and <xref rid="fig12" ref-type="fig">Fig. 12A</xref>). Compound 7a established four hydrogen bonds with Ser177, Ser176, and Thr153, along with hydrophobic interactions involving Trp102, Gln197, Arg77, and Cys149 residues (<xref rid="fig13" ref-type="fig">Fig. 13</xref>). On the other hand, compound 7g displayed three hydrogen bonds with Lys198, Trp102, and Gly10, in addition to the six pi&#x02013;pi stacked, pi&#x02013;alkyl, pi&#x02013;cation, and van der Waals interactions with the amino acids Pro11, Phe80, Trp102, Arg77, Lys198, and Gln197 similar to the co-crystalline ligand (<xref rid="fig14" ref-type="fig">Fig. 14</xref>).</p><fig position="float" id="fig13"><label>Fig. 13</label><caption><title>(A) 3D conformations of compound 7a within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>). (B) 2D conformations of compound 7a within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>).</title></caption><graphic xlink:href="d4ra08958h-f13" position="float"/></fig><fig position="float" id="fig14"><label>Fig. 14</label><caption><title>(A) 3D conformations of compound 7g within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>). (B) 2D conformations of compound 7g within the active site of phosphoserine aminotransferase (PDB ID: <uri>7T7J</uri>).</title></caption><graphic xlink:href="d4ra08958h-f14" position="float"/></fig></sec></sec><sec><title>Materials and methods</title><sec><title>Chemistry</title><p>Melting points were measured with an Electrothermal 9100 apparatus and were uncorrected. The IR spectra were recorded using a FTIR Bruker-vector 22 spectrophotometer and KBr pellets. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded in CDCl<sub>3</sub> or DMSO-<italic toggle="yes">d</italic><sub>6</sub> as a solvent on the Varian Gemini NMR spectrometer at 300 MHz and 75 MHz, respectively. Chemical shifts were reported as <italic toggle="yes">&#x003b4;</italic> values in ppm. The elemental analyses were performed at the Microanalytical Center, Cairo University. 6-Methyl-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2<italic toggle="yes">H</italic>)-one 6&#x02009;<sup><xref rid="cit16" ref-type="bibr">16</xref></sup> and hydrazonoyl halides 1&#x02009;<sup><xref rid="cit17" ref-type="bibr">17&#x02013;21</xref></sup> were prepared using the reported procedures.</p><sec><title>Synthesis of 6-methyl-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one derivatives (7a&#x02013;j)</title><p>To a mixture of hydrazonoyl halides 1a&#x02013;j (2 mmol) and 6-methyl-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2<italic toggle="yes">H</italic>)-one 3 (0.29 g, 2 mmol) in chloroform (20 mL), triethylamine (0.2 mL, 2 mmol) was added. The reaction mixture was refluxed for 6 h and then cooled; the excess chloroform was removed under reduced pressure and the residue was treated with ethanol (10 mL). The precipitated solid was collected and crystallized from a suitable solvent to give [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j). All the synthesized compounds and their physical properties are listed below:</p><sec><title>3,6-Dimethyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7a)</title><p>Brown crystals (EtOH + DMF); mp 262&#x02013;264 &#x000b0;C; yield (67%); <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 2.32 (s, 3H, CH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>), 8.38 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.47 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 16.5, 18.4, 118.9, 124.5, 138.9, 145.7, 151.8, 153.0, 155.3, 161.7. Anal. calcd for C<sub>12</sub>H<sub>10</sub>N<sub>6</sub>O<sub>3</sub> (286.25), C, 50.35; H, 3.52; N, 29.36. Found, C, 50.46; H, 3.39; N, 29.47.</p></sec><sec><title>3-Ethyl-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7b)</title><p>Brown crystals (EtOH); mp 200&#x02013;202 &#x000b0;C; yield (69%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 1.48 (t, 3H, CH<sub>2</sub>C&#x00048;&#x00332;<sub>3</sub>, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 2.45 (s, 3H, CH<sub>3</sub>), 3.03 (q, 2H, C&#x00048;&#x00332;<sub>2</sub>CH<sub>3</sub>, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 8.30 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.45 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 9.7, 17.5, 18.2, 119.5, 124.7, 141.0, 145.2, 147.9, 148.0, 155.7, 161.5. Anal. calcd for C<sub>13</sub>H<sub>12</sub>N<sub>6</sub>O<sub>3</sub> (300.28), C, 52.00; H, 4.03; N, 27.99. Found, C, 52.11; H, 4.15; N, 27.86.</p></sec><sec><title>6-Methyl-1-(4-nitrophenyl)-3-propyl-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7c)</title><p>Brown crystals (DMF); mp 202&#x02013;204 &#x000b0;C; yield (64%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 1.13 (t, 3H, CH<sub>2</sub>CH<sub>2</sub>C&#x00048;&#x00332;<sub>3</sub>, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 1.91&#x02013;1.99 (m, 2H, CH<sub>2</sub>C&#x00048;&#x00332;<sub>2</sub>CH<sub>3</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 3.00 (t, 2H, C&#x00048;&#x00332;<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 8.34 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.49 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 13.6, 18.4, 19.2, 25.6, 119.7, 124.9, 141.2, 145.5, 147.0, 148.1, 156.0, 161.6. Anal. calcd for C<sub>14</sub>H<sub>14</sub>N<sub>6</sub>O<sub>3</sub> (314.31), C, 53.50; H, 4.49; N, 26.74. Found, C, 53.61; H, 4.37; N, 26.87.</p></sec><sec><title>3-Isopropyl-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7d)</title><p>Brown crystals (EtOH); mp 208&#x02013;210 &#x000b0;C; yield (66%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 1.52 (d, 6H, CH(C&#x00048;&#x00332;<sub>3</sub>)<sub>2</sub>, <italic toggle="yes">J</italic> &#x02248; 7 Hz), 2.47 (s, 3H, CH<sub>3</sub>), 3.43&#x02013;3.52 (m, 1H, C&#x00048;&#x00332;(CH<sub>3</sub>)<sub>2</sub>), 8.32 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.48 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 18.3, 19.1, 24.9, 119.6, 124.7, 141.1, 145.2, 148.1, 150.9, 155.6, 161.5. Anal. calcd for C<sub>14</sub>H<sub>14</sub>N<sub>6</sub>O<sub>3</sub> (314.31), C, 53.50; H, 4.49; N, 26.74. Found, C, 53.60; H, 4.38; N, 26.86.</p></sec><sec><title>3-Isobutyl-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7e)</title><p>Brown crystals (EtOH); mp 202&#x02013;204 &#x000b0;C; yield (63%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 1.12 (d, 6H, CH<sub>2</sub>CH(C&#x00048;&#x00332;<sub>3</sub>)<sub>2</sub>, <italic toggle="yes">J</italic> &#x02248; 7 Hz), 2.30&#x02013;2.39 (m, 1H, CH<sub>2</sub>C&#x00048;&#x00332;(CH<sub>3</sub>)<sub>2</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 2.93 (d, 2H, C&#x00048;&#x00332;<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, <italic toggle="yes">J</italic> &#x02248; 7 Hz), 8.36 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.50 (d, 2H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 18.4, 22.3, 26.4, 32.2, 94.7, 119.7, 124.9, 141.1, 145.5, 146.4, 156.0, 161.6. Anal. calcd for C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>O<sub>3</sub> (328.33), C, 54.87; H, 4.91; N, 25.60. Found, C, 54.99; H, 4.79; N, 25.72.</p></sec><sec><title>6-Methyl-1-phenyl-3-(<italic toggle="yes">p</italic>-tolyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7f)</title><p>Beige crystals (DMF); mp 250&#x02013;252 &#x000b0;C; yield (72%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 2.47 (s, 3H, CH<sub>3</sub>), 2.53 (s, 3H, CH<sub>3</sub>), 7.33&#x02013;7.38 (m, 3H, Ar-H), 7.51 (t, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 8.18&#x02013;8.24 (m, 4H, Ar-H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 18.4, 20.9, 121.6, 125.1, 126.4, 128.7, 129.2, 131.5, 138.5, 140.9, 147.9, 151.4, 152.8, 161.7. Anal. calcd for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O (317.35), C, 68.13; H, 4.76; N, 22.07. Found, C, 68.25; H, 4.63; N, 22.18.</p></sec><sec><title>3-(4-Methoxyphenyl)-6-methyl-1-phenyl-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7g)</title><p>White crystals (DMF); mp 256&#x02013;258 &#x000b0;C; yield (70%). <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 2.34 (s, 3H, CH<sub>3</sub>), 3.87 (s, 3H, OCH<sub>3</sub>), 7.20 (d, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 7.42 (t, 1H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 7.60 (t, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 8.12 (d, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 9 Hz), 8.19 (d, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 18.2, 55.5, 113.8, 120.7, 122.8, 126.3, 128.9, 130.8, 138.4, 147.9, 151.4, 152.6, 160.4, 161.8. Anal. calcd for C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub> (333.35), C, 64.86; H, 4.54; N, 21.01. Found, C, 64.98; H, 4.41; N, 21.14.</p></sec><sec><title>3-(4-Chlorophenyl)-6-methyl-1-phenyl-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7h)</title><p>Yellow crystals (DMF); mp 245&#x02013;247 &#x000b0;C; yield (74%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 2.54 (s, 3H, CH<sub>3</sub>), 7.38 (t, 1H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 7.49&#x02013;7.58 (m, 4H, Ar-H), 8.22 (d, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 8 Hz), 8.31 (d, 2H, Ar-H, <italic toggle="yes">J</italic> &#x02248; 9 Hz); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) <italic toggle="yes">&#x003b4;</italic> 18.6, 120.4, 122.0, 127.5, 128.0, 129.3, 131.9, 136.0, 138.1, 148.0, 151.9, 155.9, 161.9. Anal. calcd for C<sub>17</sub>H<sub>12</sub>ClN<sub>5</sub>O (337.77), C, 60.45; H, 3.58; N, 20.73. Found, C, 60.57; H, 3.72; N, 20.86.</p></sec><sec><title>3-(Furan-2-yl)-6-methyl-1-(4-nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7i)</title><p>Pale brown crystals (CH<sub>3</sub>CN); mp 269&#x02013;271 &#x000b0;C; yield (71%). <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 2.39 (s, 3H, CH<sub>3</sub>), 6.87&#x02013;6.89 (m, 1H, furyl-H), 7.66 (d, 1H, furyl-H, <italic toggle="yes">J</italic> &#x02248; 3 Hz), 8.15 (d, 1H, furyl-H, <italic toggle="yes">J</italic> &#x02248; 1 Hz), 8.41&#x02013;8.49 (m, 4H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>); <sup>13</sup>C NMR (75 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 18.2, 112.6, 117.1, 119.8, 125.3, 136.5, 137.4, 141.2, 145.0, 147.1, 148.3, 154.9, 160.8. Anal. calcd for C<sub>15</sub>H<sub>10</sub>N<sub>6</sub>O<sub>4</sub> (338.28), C, 53.26; H, 2.98; N, 24.84. Found, C, 53.38; H, 2.86; N, 24.95.</p></sec><sec><title>6-Methyl-1-(4-nitrophenyl)-3-(thiophen-2-yl)-[1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7(1<italic toggle="yes">H</italic>)-one (7j)</title><p>Pale brown crystals (DMF); mp 242&#x02013;244 &#x000b0;C; yield (69%). <sup>1</sup>H NMR (300 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 2.38 (s, 3H, CH<sub>3</sub>), 7.36 (t, 1H, thieny-H, <italic toggle="yes">J</italic> &#x02248; 5 Hz), 8.05 (d, 1H, thieny-H, <italic toggle="yes">J</italic> &#x02248; 5 Hz), 8.22 (d, 1H, thieny-H, <italic toggle="yes">J</italic> &#x02248; 5 Hz), 8.38&#x02013;8.47 (m, 4H, 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>); <sup>13</sup>C NMR (75 MHz, DMSO-<italic toggle="yes">d</italic><sub>6</sub>) <italic toggle="yes">&#x003b4;</italic> 18.3, 119.7, 120.4, 123.4, 125.3, 128.6, 131.7, 132.2, 139.9, 141.1, 144.9, 154.8, 160.8. Anal. calcd for C<sub>15</sub>H<sub>10</sub>N<sub>6</sub>O<sub>3</sub>S (354.34), C, 50.84; H, 2.84; N, 23.72. Found, C, 50.95; H, 2.71; N, 23.85.</p></sec></sec></sec><sec><title>Anti-cancer activity</title><sec><title>MTT cytotoxicity assay</title><p>Cell viability was tested using the MTT assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (Bio Basic Canada Inc. Toronto, Canada).<sup><xref rid="cit26" ref-type="bibr">26</xref></sup> Under class II biosafety regulations, the procedures were carried out in a sterile laminar air flow cabinet (Baker, SG403INT; Sanford, ME, USA). Cell lines were obtained from the American type culture collection (ATCC) as a gift from Dr Stig Linder, Karonisca Institute, Sweden. All incubations were performed at 37 &#x000b0;C in a 5% CO<sub>2</sub> incubator with a 95% humidified environment (Sheldon, TC2323; Cornelius, OR, USA). 96-well micro titer polypropylene plates were seeded with cells at a density of 10<sup>4</sup> cells per well in complete DMEM media, and the cells were allowed to adhere for 24 hours. After the media was aspirated, the tested compounds were added to the cells in a single dose of 100 &#x003bc;g ml<sup>&#x02212;1</sup> in DMSO. Each well received 40 &#x003bc;l of MTT salt (2.5 g ml<sup>&#x02212;1</sup>) following a 48 hour incubation period. 200 &#x003bc;l of 10% sodium dodecyl sulfate (SDS) was added to each well after the reaction ended, and any formazan crystals that could have been produced were dissolved by two hours of incubator heating to 37 &#x000b0;C. The amount of formazan product was measured at 595 nm using a microplate reader (Bio-Rad Laboratories, model 3350, California, USA) with a reference wavelength of 690 nm, serving as a backdrop. Rather than the drugs under investigation, the medium was applied to the untreated cells (negative control). The examined compounds were dissolved in dimethylsulfoxide (DMSO), and the final concentration in the cells was less than 0.2%. For each compound and the control, the solvent concentration was the same. By applying different concentrations of 0, 6.25, 12.2, 25, and 50 &#x003bc;g ml<sup>&#x02212;1</sup> (three replicates), the concentration required for 50% inhibition of cell viability (IC<sub>50</sub>) was estimated for the potential compounds, which demonstrated preliminary cytotoxic effects at 100 &#x003bc;g ml<sup>&#x02212;1</sup>.</p></sec></sec><sec><title>Gene expression analysis</title><sec><title>Quantitative real-time PCR method</title><sec><title>RNA isolation and reverse transcription (RT) reaction</title><p>The RNeasy Mini Kit (Qiagen, Hilden, Germany), augmented with a DNaseI (Qiagen) digestion step, was employed to extract total RNA from lung cancer cell lines following the manufacturer's procedure. The isolated total RNA was treated with one unit of RQ1 RNAse-free DNAse (Invitrogen, Germany) to eliminate DNA remnants, re-suspended in DEPC-treated water, and quantified photometrically at 260 nm. The purity of total RNA was evaluated using the 260/280 nm ratio, which ranged from 1.8 to 2.1.<sup><xref rid="cit27" ref-type="bibr">27</xref></sup></p><p>Furthermore, integrity was confirmed using ethidium bromide-stained examination of 28S and 18S bands <italic toggle="yes">via</italic> formaldehyde-containing agarose gel electrophoresis. Aliquots were utilized immediately for reverse transcription (RT); otherwise, they were preserved at &#x02212;80 &#x000b0;C.</p><p>The poly(A) + RNA extracted from the lung cancer cell lines was reverse transcribed into the cDNA in a total amount of 20 &#x003bc;l utilizing the Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas, Germany). A total of 5 &#x003bc;g of RNA was utilized with a master mix. The master mix comprised 50 mM MgCl<sub>2</sub>, 10&#x000d7; RT buffer (50 mM KCl; 10 mM Tris&#x02013;HCl; pH 8.3), 10 mM of each dNTP, 50 &#x003bc;M oligo-dT primer, 20 IU ribonuclease inhibitor (50 kDa recombinant enzyme to suppress RNase activity), and 50 IU MuLV reverse transcriptase. Each sample mixture was centrifuged for 30 seconds at 1000 g and thereafter transferred to the thermocycler. The RT reaction was conducted at 25 &#x000b0;C for 10 minutes, subsequently at 42 &#x000b0;C for 1 hour, and concluded with a denaturation phase at 99 &#x000b0;C for 5 minutes. Subsequently, the reaction tubes containing RT-prepared samples were rapidly chilled in an ice chamber prior to cDNA amplification <italic toggle="yes">via</italic> the quantitative real-time polymerase chain reaction (qRT-PCR).</p></sec><sec><title>Quantitative real-time-PCR (qRT-PCR)</title><p>The cDNA copy number of lung cancer cell lines was determined using the StepOne&#x02122; Real-Time PCR System from Applied Biosystems (Thermo Fisher Scientific, Waltham, MA, USA).</p><p>The PCR reactions were prepared in 25 &#x003bc;l mixes comprising 12.5 &#x003bc;l of 1&#x000d7; SYBR&#x000ae; Premix Ex Taq&#x02122; (TaKaRa, Biotech. Co. Ltd), 0.5 &#x003bc;l of 0.2 &#x003bc;M sense primer, 0.5 &#x003bc;l of 0.2 &#x003bc;M antisense primer, 6.5 &#x003bc;l of distilled water, and 5 &#x003bc;l of cDNA template.</p><p>The reaction protocol was divided into three stages. The initial step was conducted at 95 &#x000b0;C for a duration of 3 minutes. The second step comprised 40 cycles, each divided into three phases: (a) 95 &#x000b0;C for 15 seconds, (b) 55 &#x000b0;C for 30 seconds, and (c) 72 &#x000b0;C for 30 seconds. The third stage comprised 71 cycles, first at 60 &#x000b0;C and subsequently increasing by approximately 0.5 &#x000b0;C every 10 seconds until 95 &#x000b0;C. Every experiment incorporated a distilled water control. The particular primer sequences for the lung cancer cell lines (BCL-2, BAX, and p53 genes, Brito <italic toggle="yes">et al.</italic>, 2012)<sup><xref rid="cit28" ref-type="bibr">28</xref></sup> were created and are presented in <xref rid="tab6" ref-type="table">Table 6</xref>. A melting curve analysis was conducted at 95.0 &#x000b0;C after each qPCR to assess the quality of the utilized primers. The relative quantification of the target gene to the reference gene was assessed using the 2<sup>&#x02212;&#x00394;&#x00394;<italic toggle="yes">C</italic><sub>T</sub></sup> method.<sup><xref rid="cit29" ref-type="bibr">29&#x02013;31</xref></sup></p><table-wrap position="float" id="tab6"><label>Table 6</label><caption><title>Primer sequences used for the qRT-PCR of lung cancer cell lines<xref rid="tab6fna" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Primer sequence</th><th rowspan="1" colspan="1">GenBank (accession no.)</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">BCL-2</td><td rowspan="1" colspan="1">F: TTCCGCGTGATTGAAGACAC</td><td rowspan="2" colspan="1">KY098818.1</td></tr><tr><td rowspan="1" colspan="1">R: ACTTCATCACTATCTCCCGGT</td></tr><tr><td rowspan="2" colspan="1">p53</td><td rowspan="1" colspan="1">F: GGAAATCTCACCCCATCCCA</td><td rowspan="2" colspan="1">AB082923.1</td></tr><tr><td rowspan="1" colspan="1">R: CAGTAAGCCAAGATCACGCC</td></tr><tr><td rowspan="2" colspan="1">BAX</td><td rowspan="1" colspan="1">F: AACATGGAGCTGCAGAGGAT</td><td rowspan="2" colspan="1">L22474.1</td></tr><tr><td rowspan="1" colspan="1">R: CCAATGTCCAGCCCATGATG</td></tr><tr><td rowspan="2" colspan="1">GAPDH</td><td rowspan="1" colspan="1">F: AGGTCGGAGTCAACGGATTT</td><td rowspan="2" colspan="1">NM_001357943.2</td></tr><tr><td rowspan="1" colspan="1">R:ATCGCCCCACTTGATTTTGG</td></tr></tbody></table><table-wrap-foot><fn id="tab6fna"><label>a</label><p>BCL-2: B-cell lymphoma-2 gene; BAX: BCL-2-associated X protein-encoding gene; p53: tumor suppressor gene; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec><title>DNA damage evaluation using the comet assay</title><p>The determination of DNA damage <italic toggle="yes">via</italic> the comet assay was conducted using lung cancer cell lines, following the methodology established by Olive <italic toggle="yes">et al.</italic> (1990).<sup><xref rid="cit32" ref-type="bibr">32</xref></sup> Following trypsin treatment to generate a single-cell suspension, approximately 1.5 &#x000d7; 10<sup>4</sup> cells were embedded in 0.75% low-gelling-temperature agarose and swiftly pipetted onto a pre-coated microscope slide.</p><p>The samples underwent lysis for 4 hours at 50 &#x000b0;C in a solution containing 0.5% SDS and 30 mM EDTA at pH 8.0. Following an overnight rinse at room temperature in a Tris/borate/EDTA buffer, pH 8.0, samples underwent electrophoresis for 25 minutes at 0.6 V cm<sup>&#x02212;1</sup> and were subsequently stained with propidium iodide. The slides were examined with a fluorescence microscope equipped with a CCD camera, and 150 individual comet images were analyzed from each sample for a tail moment, DNA content, and percentage of DNA in the tail. Approximately 100 cells were analyzed per sample to assess the percentage of cells exhibiting comet-like DNA damage.</p><p>The non-overlapping cells were randomly selected and assigned a score on a scale of 0&#x02013;3 based on the comet tail length migration and the relative proportion of DNA in the nucleus. Class 0 indicates no detectable DNA damage and no tail; class 1 indicates a tail length less than the diameter of the nucleus; class 2 indicates a tail length between 1&#x000d7; and 2&#x000d7; the nuclear diameter; and class 3 indicates a tail longer than 2&#x000d7; the diameter of the nucleus (Collins <italic toggle="yes">et al.</italic>, 1997).<sup><xref rid="cit33" ref-type="bibr">33</xref></sup></p></sec><sec><title>DNA fragmentation assay</title><sec><title>DNA gel electrophoresis laddering assay</title><p>The DNA fragmentation assay in lung cancer cell lines was performed in accordance with the protocol established by Yawata (1998)<sup><xref rid="cit34" ref-type="bibr">34</xref></sup> with some modifications. Briefly, the lung cancer cell lines (A549) exposed to different compounds such as PT1, PT7 and Doxorubicin were homogenized in 1 ml of the medium and centrifuged (10 min at 800 rpm). The low-molecular-weight genomic DNA was extracted as described in Yawata (1998).<sup><xref rid="cit34" ref-type="bibr">34</xref></sup> Approximately 1 &#x000d7; 10<sup>6</sup> cells of each treatment were plated. All the cells (including floating cells) were harvested and washed with Dulbecco's phosphate buffered saline. The cancer cells were lysed with the lysis buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), and 0.5% Triton X-100 for 30 min on ice. Lysates were vortexed and cleared by centrifugation at 10&#x02009;000 g for 20 min. Fragmented DNA in the supernatant was extracted with an equal volume of a neutral phenol&#x02009;:&#x02009;chloroform&#x02009;:&#x02009;isoamyl alcohol mixture (25&#x02009;:&#x02009;24&#x02009;:&#x02009;1) and analyzed electrophoretically on 2% agarose gels containing 0.1 &#x003bc;g ml<sup>&#x02212;1</sup> ethidium bromide.</p></sec></sec><sec><title>Diphenylamine reaction procedure</title><p>The lung cancer cell lines (A549) were used to determine the quantitative profile of the DNA fragmentation. The cell lines were collected immediately after the culture and treatment with PT1 and PT7 as well as with Dox. The cancer cells were lysed in 0.5 ml of lysis buffer containing 10 mM Tris&#x02013;HCl (pH 8), 1 mM EDTA, and 0.2% Triton X-100 and centrifuged at 10&#x02009;000 rpm (Eppendorf) for 20 min at 4 &#x000b0;C. The pellets were re-suspended in 0.5 ml of lysis buffer. To the pellets (P) and the supernatants (S), 0.5 ml of 25% tri-chloroacetic acid (TCA) was added and incubated at 4 &#x000b0;C for 24 h. The cells were then centrifuged for 20 min at 10&#x02009;000 rpm (Eppendorf) at 4 &#x000b0;C and the pellets were suspended in 80 ml of 5% TCA, followed by incubation at 83 &#x000b0;C for 20 min. Subsequently, to each cell sample, 160 ml of diphenylamine (DPA) solution [150 mg DPA in 10 ml glacial acetic acid, 150 ml of sulfuric acid and 50 ml acetaldehyde (16 mg ml<sup>&#x02212;1</sup>)] was added and incubated at room temperature for 24 h (Gibb <italic toggle="yes">et al.</italic>,<sup><xref rid="cit35" ref-type="bibr">35</xref></sup> 1997). The proportion of the fragmented DNA was calculated from the absorbance values at 600 nm wavelength using the formula:<inline-formula>% fragmented DNA = [OD(S)/[OD(S) + OD(P)]] &#x000d7; 100</inline-formula>(OD: optical density, S: supernatants, P: pellets).</p></sec><sec><title>Statistical analysis</title><p>All data were analyzed using the General Linear Model (GLM) procedure of the Statistical Analysis System (SAS) (1982),<sup><xref rid="cit36" ref-type="bibr">36</xref></sup> followed by the Scheff&#x000e9;-test to assess significant differences between groups. The values are expressed as mean &#x000b1; SEM. All statements of significance were based on a probability of <italic toggle="yes">P</italic> &#x0003c; 0.05.</p></sec><sec><title>Molecular docking simulation</title><p>The molecular docking of the most active compounds 7a and 7g with two enzymes that play an important role in lung cancer progression, namely, 3-phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase (PSAT1), was performed on Autodock 4 in PyRx software version 8.<sup><xref rid="cit37" ref-type="bibr">37,38</xref></sup> The 3D structures of the target enzymes were obtained from the RCSB protein data bank in the PDB format using codes <uri>2G76</uri> (3-phosphoglycerate dehydrogenase in complex with nicotinamide&#x02013;adenine&#x02013;dinucleotide (NAD)) and <uri>7T7J</uri> (phosphoserine aminotransferase in complex with pyridoxal-5&#x02032;-phosphate (PLP)).<sup><xref rid="cit39" ref-type="bibr">39,40</xref></sup></p><p>Before the docking process, the enzymes underwent preparation, including removal of the co-crystallized ligands and water molecules, then optimization using the <italic toggle="yes">QuickPrep</italic> tool module in the MOE program. The resulting files were saved as pdb and then converted to the PDBQT format using Autodock Vina tools. Autodock tools were employed to set the size and the center of the grid box that covers the native ligands completely. The docking protocol was validated by re-docking the co-crystallized ligands into the enzyme-active sites and the RMSD was calculated using the DockRMSD server.<sup><xref rid="cit41" ref-type="bibr">41</xref></sup> The chemical structure of the selected compounds 7a and 7g were constructed with the <italic toggle="yes">ChemDraw</italic> ultra-10.0, saved as SDF files, then minimized by applying the MMFF94 force field and converted to pdbqt files using OpenBable tools involved in PyRx software. PyRx software presented the 8 most suitable docking poses of the ligand&#x02013;protein complex after the docking was completed and subsequently ranked according to the binding energy. We selected the first docking pose, which is the most suitable pose where the ligands have the lowest binding energy, zero &#x000c5; root-mean-square deviation (RMSD) and strongly interact with the protein's catalytic cavity, and visualized using BIOVIA Discovery Studio Visualizer 2021 for insights into the ligand binding position in the protein cavity.</p></sec><sec><title>Crystallography</title><p>The data for compound 7b was collected at a low temperature (100 K) on a Rigaku XtaLAB Synergy dual microfocus X-ray diffractometer, using a PhotonJet-S series of microfocus X-ray source, Cu-K&#x003b1; radiation (<italic toggle="yes">&#x003bb;</italic> = 1.54184 &#x000c5;) and equipped with an Oxford Cryosystems Cooler Device. The cell parameters of the final unit were obtained by means of a least-squares refinement. The structure was solved by Direct Methods using SHELXT 2018/2 (ref. <xref rid="cit42" ref-type="bibr">42</xref>) and refined by means of least-squares procedures on a <italic toggle="yes">F</italic><sup>2</sup> using the program CRYSTALS.<sup><xref rid="cit43" ref-type="bibr">43</xref></sup> The Atomic Scattering Factors were taken from the International Tables for X-Ray Crystallography.<sup><xref rid="cit44" ref-type="bibr">44</xref></sup> All hydrogen atoms were geometrically placed and refined using a riding model.</p><p>All non-hydrogen atoms were anisotropically refined, and in the last cycles of refinement, a weighting scheme was used, where weights are calculated from the following formula:<inline-formula><italic toggle="yes">w</italic> = 1/[2(Fo2) + (aP)2 + bP]</inline-formula>where <italic toggle="yes">P</italic> = (Fo2 + 2Fc2)/3. Molecules were drawn with the program ORTEP32 with 30% probability displacement ellipsoids for non-hydrogen atoms.<sup><xref rid="cit45" ref-type="bibr">45</xref></sup></p></sec></sec><sec><title>Conclusions</title><p>In summary, we reported a novel series of [1,2,4]triazolo[4,3-<italic toggle="yes">b</italic>][1,2,4]triazin-7-one derivatives (7a&#x02013;j) by the reaction of 6-methyl-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2<italic toggle="yes">H</italic>)-one with the corresponding hydrazonoyl halides in chloroform. The chemical structures of these compounds were proven using spectral data, elemental analyses, and single-crystal X-ray diffraction. The anti-cancer activity of these compounds was determined against the PC3, A549, PACA2 and BJ1 using MTT assay. Two compounds, 7a and 7g, showed potent anti-cancer activities with low IC<sub>50</sub> values (36.6 and 40.1 &#x003bc;M, respectively) compared to the reference drug with an IC<sub>50</sub> value of 43.8 &#x003bc;M on lung cell lines and demonstrated safe mortality effect on the normal cell line (BJ1) with cytotoxicity percentages of 3.5% and 2.8%, respectively. These compounds (7a and 7g) were investigated further to determine their mechanism of action using DNA fragmentation, DNA damage and gene expression (BCL-2, BAX, and p53 genes). Molecular docking was employed to explore the binding affinity between the most active compounds (7a and 7g) and two key enzymes, PHGDH and PSAT1, which play vital roles in the progression of lung cancer.</p></sec><sec sec-type="data-availability"><title>Data availability</title><p>The data supporting this article (copies of <sup>1</sup>H, <sup>13</sup>C NMR spectra and single-crystal X-ray details) have been included as part of the ESI.<xref rid="fn1" ref-type="fn">&#x02020;</xref></p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>There are no conflicts to declare.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="RA-015-D4RA08958H-s001" position="float" content-type="local-data"><label>RA-015-D4RA08958H-s001</label><media xlink:href="RA-015-D4RA08958H-s001.pdf" id="d67e2639" position="anchor"/></supplementary-material><supplementary-material id="RA-015-D4RA08958H-s002" position="float" content-type="local-data"><label>RA-015-D4RA08958H-s002</label><media xlink:href="RA-015-D4RA08958H-s002.cif" id="d67e2642" position="anchor"/></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="cit1"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aggarwal</surname><given-names>R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sumran</surname><given-names>G.</given-names></name>
</person-group><article-title>An insight on medicinal attributes of 1,2,4-triazoles</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>205</volume><fpage>112652</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112652</pub-id><pub-id pub-id-type="pmid">32771798</pub-id>
</element-citation></ref><ref id="cit2"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lei</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>Construction of heterocycle-triazolotriazine framework energetic compounds: towards novel high-performance explosives</article-title><source>Chem. Commun.</source><year>2024</year><volume>60</volume><fpage>10588</fpage><lpage>10591</lpage><pub-id pub-id-type="doi">10.1039/D4CC03260H</pub-id><pub-id pub-id-type="pmid">39235278</pub-id>
</element-citation></ref><ref id="cit3"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>M.</given-names></name>
</person-group><article-title>Amino-tetrazole functionalized fused triazolo-triazine and tetrazolo-triazine energetic materials</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><fpage>6062</fpage><lpage>6065</lpage><pub-id pub-id-type="doi">10.1039/C9CC01777A</pub-id><pub-id pub-id-type="pmid">31066384</pub-id>
</element-citation></ref><ref id="cit4"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>G.</given-names></name>
</person-group><article-title>Combining 5,6-fused triazolo-triazine with pyrazole: A novel energetic framework for heat-resistant explosive</article-title><source>Chem. Eng. J.</source><year>2021</year><volume>426</volume><fpage>131297</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2021.131297</pub-id></element-citation></ref><ref id="cit5"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mojzych</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tarasiuk</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Karczmarzyk</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Juszczak</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Rzeski</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Fruzinski</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wozny</surname><given-names>A.</given-names></name>
</person-group><article-title>Synthesis, Structure and Antiproliferative Activity of New pyrazolo[4,3- e]triazolo[4,5-b][1,2,4]triazine Derivatives</article-title><source>Med. Chem.</source><year>2018</year><volume>14</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">29065838</pub-id>
</element-citation></ref><ref id="cit6"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kumaravel</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sha</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Van Vlijmen</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Bohnert</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Vu</surname><given-names>C. B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ensinger</surname><given-names>C. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Engber</surname><given-names>T. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Whalley</surname><given-names>E. T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Petter</surname><given-names>R. C.</given-names></name>
</person-group><article-title>Novel Bicyclic Piperazine Derivatives of Triazolotriazine and Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor Antagonists</article-title><source>J. Med. Chem.</source><year>2004</year><volume>47</volume><fpage>6218</fpage><lpage>6229</lpage><pub-id pub-id-type="doi">10.1021/jm0494321</pub-id><pub-id pub-id-type="pmid">15566292</pub-id>
</element-citation></ref><ref id="cit7"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guo</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>X.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhan</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ai</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Duan</surname><given-names>W.</given-names></name>
</person-group><article-title>Synthesis of triazolotriazine derivatives as c-Met inhibitors</article-title><source>Mol. Diversity</source><year>2020</year><volume>25</volume><fpage>839</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1007/s11030-020-10067-5</pub-id><pub-id pub-id-type="pmid">32157572</pub-id>
</element-citation></ref><ref id="cit8"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akahoshi</surname><given-names>F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Takeda</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Okada</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kajii</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nishimura</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sugiura</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Fukaya</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Naito</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Imagawa</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>N.</given-names></name>
</person-group><article-title>Synthesis and Pharmacological Activity of Triazolo[1,5-a]triazine Derivatives Inhibiting Eosinophilia</article-title><source>J. Med. Chem.</source><year>1998</year><volume>41</volume><fpage>2985</fpage><lpage>2993</lpage><pub-id pub-id-type="doi">10.1021/jm970759u</pub-id><pub-id pub-id-type="pmid">9685237</pub-id>
</element-citation></ref><ref id="cit9"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thai</surname><given-names>A. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>B. J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sequist</surname><given-names>L. V.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gainor</surname><given-names>J. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Heist</surname><given-names>R. S.</given-names></name>
</person-group><article-title>Lung cancer</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id><pub-id pub-id-type="pmid">34273294</pub-id>
</element-citation></ref><ref id="cit10"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ou</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>He</surname><given-names>J.</given-names></name>
</person-group><article-title>An annual review of the remarkable advances in lung cancer clinical research in 2019</article-title><source>J. Thorac. Dis.</source><year>2020</year><volume>12</volume><fpage>1056</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.21037/jtd.2020.03.11</pub-id><pub-id pub-id-type="pmid">32274174</pub-id>
</element-citation></ref><ref id="cit11"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samanci</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Celik</surname><given-names>E.</given-names></name>
</person-group><article-title>The top 100 cited articles in lung cancer &#x02013; a bibliometric analysis</article-title><source>Wsp&#x000f3;lcz. Onkol.</source><year>2020</year><volume>24</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.5114/wo.2020.94725</pub-id><pub-id pub-id-type="pmid">32514234</pub-id>
</element-citation></ref><ref id="cit12"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mridha</surname><given-names>M. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Prodeep</surname><given-names>A. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hoque</surname><given-names>A. S. M. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Islam</surname><given-names>M. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lima</surname><given-names>A. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kabir</surname><given-names>M. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hamid</surname><given-names>M. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Watanobe</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Morales</surname><given-names>R.</given-names></name>
</person-group><article-title>A Comprehensive Survey on the Progress, Process, and Challenges of Lung Cancer Detection and Classification</article-title><source>J. Healthc. Eng.</source><year>2022</year><volume>2022</volume><fpage>1</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1155/2022/5905230</pub-id><pub-id pub-id-type="pmid">36569180</pub-id>
</element-citation></ref><ref id="cit13"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barr</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
</person-group><article-title>Recent advances and remaining challenges in lung cancer therapy</article-title><source>Chin. Med. J.</source><year>2024</year><volume>137</volume><fpage>533</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1097/CM9.0000000000002991</pub-id><pub-id pub-id-type="pmid">38321811</pub-id>
</element-citation></ref><ref id="cit14"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>G. S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Baldwin</surname><given-names>D. R.</given-names></name>
</person-group><article-title>Recent advances in the management of lung cancer</article-title><source>Clin. Med.</source><year>2018</year><volume>18</volume><fpage>s41</fpage><lpage>s46</lpage><pub-id pub-id-type="doi">10.7861/clinmedicine.18-2-s41</pub-id><pub-id pub-id-type="pmid">29700092</pub-id>
</element-citation></ref><ref id="cit15"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scharnetzki</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Schiller</surname><given-names>J. H.</given-names></name>
</person-group><article-title>Lung Cancer</article-title><source>Chest</source><year>2021</year><volume>159</volume><fpage>1721</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2020.12.043</pub-id><pub-id pub-id-type="pmid">33965131</pub-id>
</element-citation></ref><ref id="cit16"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Falco</surname><given-names>E. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pappas</surname><given-names>E.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hitchings</surname><given-names>G. H.</given-names></name>
</person-group><article-title>1,2,4-Triazine Analogs of the Natural Pyrimidines</article-title><source>J. Am. Chem. Soc.</source><year>2002</year><volume>78</volume><fpage>1938</fpage><lpage>1941</lpage><pub-id pub-id-type="doi">10.1021/ja01590a047</pub-id></element-citation></ref><ref id="cit17"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hassaneen</surname><given-names>H. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mousa</surname><given-names>H. A. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abed</surname><given-names>N. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Shawali</surname><given-names>A. S.</given-names></name>
</person-group><article-title>Chemistry of C-Heteroarylhydrazidoyl Halides. Synthesis and Reactions of N-(p-Nitrophenyl)-C-(2-thienyl)-formohydrazidoyl Halides</article-title><source>Heterocycles</source><year>1988</year><volume>27</volume><fpage>695</fpage><pub-id pub-id-type="doi">10.3987/COM-87-4381</pub-id></element-citation></ref><ref id="cit18"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katada</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Eguchi</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sasaki</surname><given-names>T.</given-names></name>
</person-group><article-title>Thermal cycloaddition reactions of thiocarbonyl compounds. Part 2. 1,3-dipolar cycloaddition reactions of adamantanethione with nitrile oxides, nitrilimines, and diazoalkanes</article-title><source>J. Chem. Soc., Perkin Trans. 1</source><year>1984</year><fpage>2641</fpage><pub-id pub-id-type="doi">10.1039/P19840002641</pub-id></element-citation></ref><ref id="cit19"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rateb</surname><given-names>N. M.</given-names></name>
</person-group><article-title>Synthesis of Some New Thiazole, Thiophene, and 2,3-Dihydro-1,3,4-thiadiazole and Pyrimidino[1,2-b]indazole Derivatives</article-title><source>Phosphorus, Sulfur, Silicon Relat. Elem.</source><year>2005</year><volume>180</volume><fpage>2361</fpage><lpage>2372</lpage><pub-id pub-id-type="doi">10.1080/104265090921083</pub-id></element-citation></ref><ref id="cit20"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rector</surname><given-names>D. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Folz</surname><given-names>S. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Conklin</surname><given-names>R. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Nowakowski</surname><given-names>L. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Kaugars</surname><given-names>G.</given-names></name>
</person-group><article-title>Structure-activity relationships in a broad-spectrum anthelmintic series. Acid chloride phenylhydrazones. I. Aryl substitutions and chloride variations</article-title><source>J. Med. Chem.</source><year>2002</year><volume>24</volume><fpage>532</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1021/jm00137a011</pub-id><pub-id pub-id-type="pmid">7241511</pub-id>
</element-citation></ref><ref id="cit21"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hegarty</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cashman</surname><given-names>M. P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>F. L.</given-names></name>
</person-group><article-title>Synthesis of aliphatic hydrazonyl bromides and kinetics of their conversion into hydrazides</article-title><source>J. Chem. Soc., Perkin Trans. 2</source><year>1972</year><fpage>1381</fpage><pub-id pub-id-type="doi">10.1039/P29720001381</pub-id></element-citation></ref><ref id="cit22"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daunis</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Maury</surname><given-names>G.</given-names></name>
</person-group><article-title>Heteroaromatic 10-.pi.-electron systems. New s-triazolo-as-triazines with a bridgehead nitrogen atom</article-title><source>J. Org. Chem.</source><year>2002</year><volume>42</volume><fpage>1018</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1021/jo00426a019</pub-id></element-citation></ref><ref id="cit23"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tisler</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Vrbaski</surname><given-names>Z.</given-names></name>
</person-group><article-title>Reaction of 4-Arylthiosemicarbazides with Some &#x003b1;-Keto Acids and Synthesis of Some Substituted 3-Thioxo-5-oxo-2,3,4,5-tetrahydro-1,2,4-triazines</article-title><source>J. Org. Chem.</source><year>2002</year><volume>25</volume><fpage>770</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1021/jo01075a024</pub-id></element-citation></ref><ref id="cit24"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-Sayed</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mahmoud</surname><given-names>K.</given-names></name>
</person-group><article-title>Novel 5-Fluorouracil analogues versus perfluorophenyl ureas as potent anti-breast cancer agents: design, robust synthesis, in vitro, molecular docking, pharmacokinetics ADMET analysis and dynamic simulations</article-title><source>Bioorg. Chem.</source><year>2024</year><volume>153</volume><fpage>107944</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2024.107944</pub-id><pub-id pub-id-type="pmid">39532011</pub-id>
</element-citation></ref><ref id="cit25"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Basyouni</surname><given-names>W. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tohamy</surname><given-names>W. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelhafez</surname><given-names>T. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-awady</surname><given-names>M. K.</given-names></name>
</person-group><article-title>Novel pyrrolo[2,3-d]pyrimidine derivatives: Design, synthesis, structure elucidation and <italic toggle="yes">in vitro</italic> anti-BVDV activity</article-title><source>Tetrahedron</source><year>2019</year><volume>75</volume><fpage>130749</fpage><pub-id pub-id-type="doi">10.1016/j.tet.2019.130749</pub-id></element-citation></ref><ref id="cit26"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Othman</surname><given-names>A. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mahmoud</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mahrous</surname><given-names>K. F.</given-names></name>
</person-group><article-title>New 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-one derivatives as antimicrobial and anti-cancer agents: Synthesis, in-vitro and SAR studies</article-title><source>J. Mol. Struct.</source><year>2023</year><volume>1294</volume><fpage>136516</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2023.136516</pub-id></element-citation></ref><ref id="cit27"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Elhakim</surname><given-names>H. K. A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelrehim</surname><given-names>S. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mahrous</surname><given-names>K. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-Sayed</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelhamid</surname><given-names>I. A.</given-names></name>
</person-group><article-title>New cyano-acrylamide derivatives incorporating the thiophene moiety: Synthesis, anti-cancer, gene expression, DNA fragmentation, DNA damage, and <italic toggle="yes">in silico</italic> studies</article-title><source>J. Mol. Struct.</source><year>2025</year><volume>1321</volume><fpage>140001</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2024.140001</pub-id></element-citation></ref><ref id="cit28"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brito</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abrantes</surname><given-names>A. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Pinto-Costa</surname><given-names>C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gomes</surname><given-names>A. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mamede</surname><given-names>A. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Casalta-Lopes</surname><given-names>J.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Gon&#x000e7;alves</surname><given-names>A. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sarmento-Ribeiro</surname><given-names>A. B.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Tralh&#x000e3;o</surname><given-names>J. G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Botelho</surname><given-names>M. F.</given-names></name>
</person-group><article-title>Hepatocellular Carcinoma and Chemotherapy: The Role of p53</article-title><source>Chemotherapy</source><year>2012</year><volume>58</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1159/000343656</pub-id><pub-id pub-id-type="pmid">23257706</pub-id>
</element-citation></ref><ref id="cit29"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yasser</surname><given-names>N.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-Shorbagy</surname><given-names>H. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Eissa</surname><given-names>S. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hassaneen</surname><given-names>H. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelhamid</surname><given-names>I. A.</given-names></name>
</person-group><article-title>Synthesis, anticancer evaluation of novel hybrid pyrazole-based chalcones, molecular docking, DNA fragmentation, and gene expression: <italic toggle="yes">in vitro</italic> studies</article-title><source>RSC Adv.</source><year>2024</year><volume>14</volume><fpage>21859</fpage><lpage>21873</lpage><pub-id pub-id-type="doi">10.1039/D4RA03375B</pub-id><pub-id pub-id-type="pmid">38984258</pub-id>
</element-citation></ref><ref id="cit30"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Soliman</surname><given-names>A. A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Youssef</surname><given-names>E. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelraof</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-Sayed</surname><given-names>A. F.</given-names></name>
</person-group><article-title>Green, facile synthesis and evaluation of unsymmetrical carbamide derivatives as antimicrobial and anticancer agents with mechanistic insights</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><fpage>15441</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-65308-6</pub-id><pub-id pub-id-type="pmid">38965246</pub-id>
</element-citation></ref><ref id="cit31"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamel</surname><given-names>M. G.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hanafy</surname><given-names>M. K. H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Mahrous</surname><given-names>K. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hassaneen</surname><given-names>H. M.</given-names></name>
</person-group><article-title>Design, synthesis and potent anti-pancreatic cancer activity of new pyrazole derivatives bearing chalcone, thiazole and thiadiazole moieties: gene expression, DNA fragmentation, cell cycle arrest and SAR</article-title><source>RSC Adv.</source><year>2024</year><volume>14</volume><fpage>26954</fpage><lpage>26970</lpage><pub-id pub-id-type="doi">10.1039/D4RA03005B</pub-id><pub-id pub-id-type="pmid">39193301</pub-id>
</element-citation></ref><ref id="cit32"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Olive</surname><given-names>P. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ban&#x000e1;th</surname><given-names>J. P.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Durand</surname><given-names>R. E.</given-names></name>
</person-group><article-title>Heterogeneity in Radiation-Induced DNA Damage and Repair in Tumor and Normal Cells Measured Using the &#x0201c;Comet&#x0201d; Assay</article-title><source>Radiat. Res.</source><year>2012</year><volume>178</volume><fpage>AV35</fpage><lpage>AV42</lpage><pub-id pub-id-type="doi">10.1667/RRAV04.1</pub-id><pub-id pub-id-type="pmid">22870978</pub-id>
</element-citation></ref><ref id="cit33"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Dusinska</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Franklin</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Somorovska</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Petrovska</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Duthie</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Fillion</surname><given-names>L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Panayiotidis</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Raslova</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Vaughan</surname><given-names>N.</given-names></name>
</person-group><article-title>Comet assay in human biomonitoring studies: Reliability, validation, and applications</article-title><source>Environ. Mol. Mutagen.</source><year>1997</year><volume>30</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2280(1997)30:2&#x0003c;139::AID-EM6&#x0003e;3.0.CO;2-I</pub-id><pub-id pub-id-type="pmid">9329638</pub-id>
</element-citation></ref><ref id="cit34"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yawata</surname><given-names>A.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Adachi</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Okuda</surname><given-names>H.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Naishiro</surname><given-names>Y.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Takamura</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Hareyama</surname><given-names>M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Takayama</surname><given-names>S.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Reed</surname><given-names>J. C.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Imai</surname><given-names>K.</given-names></name>
</person-group><article-title>Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells</article-title><source>Oncogene</source><year>1998</year><volume>16</volume><fpage>2681</fpage><lpage>2686</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201792</pub-id><pub-id pub-id-type="pmid">9632144</pub-id>
</element-citation></ref><ref id="cit35"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gibb</surname><given-names>R. K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>D. D.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Wan</surname><given-names>T.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>O&#x02019;Connor</surname><given-names>D. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Doering</surname><given-names>D. L.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Ger&#x000e7;el-Taylor</surname><given-names>&#x000c7;.</given-names></name>
</person-group><article-title>Apoptosis as a Measure of Chemosensitivity to Cisplatin and Taxol Therapy in Ovarian Cancer Cell Lines</article-title><source>Gynecol. Oncol.</source><year>1997</year><volume>65</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1006/gyno.1997.4637</pub-id><pub-id pub-id-type="pmid">9103385</pub-id>
</element-citation></ref><ref id="cit36"><mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>SAS Institute</surname></name>
</person-group>, <source>SAS User's Guide: Statistics</source>, <publisher-name>SAS Institute</publisher-name>, <publisher-loc>Cary, N.C.</publisher-loc>, <year>1982</year></mixed-citation></ref><ref id="cit37"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trott</surname><given-names>O.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Olson</surname><given-names>A. J.</given-names></name>
</person-group><article-title>AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J. Comput. Chem.</source><year>2009</year><volume>31</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id>
</element-citation></ref><ref id="cit38"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sroor</surname><given-names>F. M.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>El-Sayed</surname><given-names>A. F.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Abdelraof</surname><given-names>M.</given-names></name>
</person-group><article-title>Design, synthesis, structure elucidation, antimicrobial, molecular docking, and SAR studies of novel urea derivatives bearing tricyclic aromatic hydrocarbon rings</article-title><source>Arch. Pharm.</source><year>2024</year><volume>357</volume><fpage>2300738</fpage><pub-id pub-id-type="doi">10.1002/ardp.202300738</pub-id><pub-id pub-id-type="pmid">38466125</pub-id>
</element-citation></ref><ref id="cit39"><mixed-citation publication-type="other">
<uri xlink:href="https://www.rcsb.org/structure/7T7J">https://www.rcsb.org/structure/7T7J</uri>
</mixed-citation></ref><ref id="cit40"><mixed-citation publication-type="other">
<uri xlink:href="https://www.rcsb.org/structure/2g76">https://www.rcsb.org/structure/2g76</uri>
</mixed-citation></ref><ref id="cit41"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bell</surname><given-names>E. W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group><article-title>DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism</article-title><source>J. Cheminf.</source><year>2019</year><volume>11</volume><fpage>40</fpage></element-citation></ref><ref id="cit42"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheldrick</surname><given-names>G. M.</given-names></name>
</person-group><article-title>A short history ofSHELX</article-title><source>Acta Crystallogr., Sect. A:Found. Adv.</source><year>2007</year><volume>64</volume><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1107/S0108767307043930</pub-id><pub-id pub-id-type="pmid">18156677</pub-id>
</element-citation></ref><ref id="cit43"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Betteridge</surname><given-names>P. W.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Carruthers</surname><given-names>J. R.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>R. I.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Prout</surname><given-names>K.</given-names></name>
</person-group><person-group person-group-type="author">
<name><surname>Watkin</surname><given-names>D. J.</given-names></name>
</person-group><article-title>CRYSTALSversion 12: software for guided crystal structure analysis</article-title><source>J. Appl. Crystallogr.</source><year>2003</year><volume>36</volume><fpage>1487</fpage><pub-id pub-id-type="doi">10.1107/S0021889803021800</pub-id></element-citation></ref><ref id="cit44"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moss</surname><given-names>D. S.</given-names></name>
</person-group><article-title>International tables for X-ray crystallography. Vol. IV edited by J. A. Ibers and W. C. Hamilton</article-title><source>Acta Crystallogr.</source><year>1975</year><volume>31</volume><fpage>2558</fpage><pub-id pub-id-type="doi">10.1107/S0567740875008175</pub-id></element-citation></ref><ref id="cit45"><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farrugia</surname><given-names>L. J.</given-names></name>
</person-group><article-title>ORTEP-3 for Windows - a version ofORTEP-III with a Graphical User Interface (GUI)</article-title><source>J. Appl. Crystallogr.</source><year>1997</year><volume>30</volume><fpage>565</fpage><pub-id pub-id-type="doi">10.1107/S0021889897003117</pub-id></element-citation></ref></ref-list></back></article>